University of Dundee

The trans-ancestral genomic architecture of glycemc traits

LifeLines Cohort Study; Chen, Ji; Spracklen, Cassandra N.; Marenne, Gaëlle; Varshney, Arushi

Published in:
Nature Genetics

DOI:
[10.1038/s41588-021-00852-9](https://doi.org/10.1038/s41588-021-00852-9)

Publication date:
2021

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

LifeLines Cohort Study, Chen, J., Spracklen, C. N., Marenne, G., Varshney, A., Corbin, L. J., Luan, J., Willems, S. M., Wu, Y., Zhang, X., Horikoshi, M., Boutin, T. S., Mägi, R., Waage, J., Li-Gao, R., Chan, K. H. K., Yao, J., Anasanti, M. D., ... Barroso, I. (2021). The trans-ancestral genomic architecture of glycemc traits. *Nature Genetics*, 53(6), 840-860. <https://doi.org/10.1038/s41588-021-00852-9>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

The Trans-Ancestral Genomic Architecture of Glycemic Traits

Ji Chen^{1,2#}, Cassandra N. Spracklen^{3,4#}, Gaëlle Marenne^{2,5#}, Arushi Varshney^{6#}, Laura J Corbin^{7,8#}, Jian'an Luan⁹, Sara M Willems⁹, Ying Wu³, Xiaoshuai Zhang^{9,10}, Momoko Horikoshi^{11,12,13}, Thibaud S Boutin¹⁴, Reedik Mägi¹⁵, Johannes Waage^{16,17}, Achilleas Pitsilides¹⁸, Ruifang Li-Gao¹⁹, Kei Hang Katie Chan^{20,21,22}, Jie Yao²³, Mila D Anasanti²⁴, Audrey Y Chu²⁵, Annique Claringbould²⁶, Jani Heikkinen²⁴, Jaeyoung Hong¹⁸, Jouke-Jan Hottenga^{27,28}, Shaofeng Huo²⁹, Marika A. Kaakinen^{30,24}, Tin Louie³¹, Winfried März^{32,33,34}, Hortensia Moreno-Macias³⁵, Anne Ndungu¹², Sarah C. Nelson³¹, Ilja M. Nolte³⁶, Kari E North³⁷, Chelsea K. Raulerson³, Debashree Ray³⁸, Rebecca Rohde³⁷, Denis Rybin¹⁸, Claudia Schurmann^{39,40}, Xueling Sim^{41,42,43}, Loz Southam², Isobel D Stewart⁹, Carol A. Wang⁴⁴, Yujie Wang³⁷, Peitao Wu¹⁸, Weihua Zhang^{45,46}, Tarunveer S. Ahluwalia^{16,17,47}, Emil VR Appel⁴⁸, Lawrence F. Bielak⁴⁹, Jennifer A. Brody⁵⁰, Noël P Burt⁵¹, Claudia P Cabrera^{52,53}, Brian E Cade^{54,55}, Jin Fang Chai⁴¹, Xiaoran Chai^{56,57}, Li-Ching Chang⁵⁸, Chien-Hsiun Chen⁵⁸, Brian H Chen⁵⁹, Kumaraswamy Naidu Chitrala⁶⁰, Yen-Feng Chiu⁶¹, Hugoline G. de Haan¹⁹, Graciela E Delgado³⁴, Ayse Demirkan^{62,30}, Qing Duan^{3,63}, Jorgen Engmann⁶⁴, Segun A Fatumo^{65,66,67}, Javier Gayán⁶⁸, Franco Giulianini⁶⁹, Jung Ho Gong²⁰, Stefan Gustafsson⁷⁰, Yang Hai⁷¹, Fernando P Hartwig^{72,7}, Jing He⁷³, Yoriko Heianza⁷⁴, Tao Huang⁷⁵, Alicia Huerta-Chagoya^{76,77}, Mi Yeong Hwang⁷⁸, Richard A. Jensen⁵⁰, Takahisa Kawaguchi⁷⁹, Katherine A Kentistou^{80,81}, Young Jin Kim⁷⁸, Marcus E Kleber³⁴, Ishminder K Kooner⁴⁶, Shuiqing Lai²⁰, Leslie A Lange⁸², Carl D Langefeld⁸³, Marie Lauzon²³, Man Li⁸⁴, Symen Ligthart⁶², Jun Liu^{62,85}, Marie Loh^{86,45}, Jirong Long⁸⁷, Valeriya Lyssenko^{88,89}, Massimo Mangino^{90,91}, Carola Marzi^{92,93}, May E Montasser⁹⁴, Abhishek Nag¹², Masahiro Nakatochi⁹⁵, Damia Noce⁹⁶, Raymond Noordam⁹⁷, Giorgio Pistis⁹⁸, Michael Preuss^{39,99}, Laura Raffield³, Laura J. Rasmussen-Torvik¹⁰⁰, Stephen S Rich^{101,102}, Neil R Robertson^{11,12}, Rico Rueedi^{103,104}, Kathleen Ryan⁹⁴, Serena Sanna^{98,26}, Richa Saxena^{105,106,107}, Katharina E Schraut^{80,81}, Bengt Sennblad¹⁰⁸, Kazuya Setoh⁷⁹, Albert V Smith^{109,110}, Lorraine Southam^{111,112}, Thomas Sparsø⁴⁸, Rona J Strawbridge^{113,114}, Fumihiko Takeuchi¹¹⁵, Jingyi Tan²³, Stella Trompet^{97,116}, Erik van den Akker^{117,118,119}, Peter J van der Most³⁶, Niek Verweij^{120,121}, Mandy Vogel¹²², Heming Wang^{54,55}, Chaolong Wang^{123,124}, Nan Wang^{125,126}, Helen R Warren^{52,53}, Wanqing Wen⁸⁷, Tom Wilsgaard¹²⁷, Andrew Wong¹²⁸, Andrew R Wood¹, Tian Xie³⁶, Mohammad Hadi Zafarmand^{129,130}, Jing-Hua Zhao¹³¹, Wei Zhao⁴⁹, Najaf Amin^{62,85}, Zorayr Arzumanyan²³, Arne Astrup¹³², Stephan JL Bakker¹³³, Damiano Baldassarre^{134,135}, Marian Beekman¹¹⁷, Richard N Bergman¹³⁶, Alain Bertoni¹³⁷, Matthias Blüher¹³⁸, Lori L. Bonnycastle¹³⁹, Stefan R Bornstein¹⁴⁰, Donald W Bowden¹⁴¹, Qiuyin Cai⁷³, Archie Campbell^{142,143}, Harry Campbell⁸⁰, Yi Cheng Chang^{144,145,146}, Eco J.C. de Geus^{27,28}, Abbas Dehghan⁶², Shufa Du¹⁴⁷, Gudny Eiriksdottir¹¹⁰, Aliko Eleni Farmaki^{148,149}, Mattias Frånberg¹⁵⁰, Christian Fuchsberger⁹⁶, Yutang Gao¹⁵¹, Anette P Gjesing⁴⁸, Anuj Goel^{152,12}, Sohee Han⁷⁸, Catharina A Hartman¹⁵³, Christian Herder^{154,155,156}, Andrew A. Hicks⁹⁶, Chang-Hsun Hsieh^{157,158}, Willa A. Hsueh¹⁵⁹, Sahoko Ichiara¹⁶⁰, Michiya Igase¹⁶¹, M. Arfan Ikram⁶², W. Craig Johnson³¹, Marit E Jørgensen^{17,162}, Peter K Joshi⁸⁰, Rita R Kalyani¹⁶³, Fouad R. Kandeel¹⁶⁴, Tomohiro Katsuya^{165,166}, Chiea Chuen Khor¹²⁴, Wieland Kiess¹²², Ivana Kolcic¹⁶⁷, Teemu Kuulasmaa¹⁶⁸, Johanna Kuusisto¹⁶⁹, Kristi Läll¹⁵, Kelvin Lam²³, Deborah A Lawlor^{170,8}, Nanette R. Lee^{171,172}, Rozenn N. Lemaitre⁵⁰, Honglan Li¹⁷³, Lifelines Cohort Study¹⁷⁴, Shih-Yi Lin^{175,176,177}, Jaana Lindström¹⁷⁸, Allan Linneberg^{179,180}, Jianjun Liu^{124,181}, Carlos Lorenzo¹⁸², Tatsuaki Matsubara¹⁸³, Fumihiko Matsuda⁷⁹, Geltrude Mingrone¹⁸⁴, Simon Mooijaart⁹⁷, Sanghoon Moon⁷⁸, Toru Nabika¹⁸⁵, Girish N. Nadkarni³⁹, Jerry L. Nadler¹⁸⁶, Mari Nelis¹⁵, Matt J Neville^{11,187}, Jill M Norris¹⁸⁸, Yasumasa Ohyaig¹⁸⁹, Annette Peters^{190,93,191}, Patricia A. Peyser⁴⁹, Ozren Polasek^{167,192}, Qibin Qi¹⁹³, Dennis Raven¹⁵³, Dermot F Reilly¹⁹⁴, Alex Reiner¹⁹⁵, Fernando Rivideneira¹⁹⁶, Kathryn Roll²³, Igor Rudan¹⁹⁷, Charumathi Sabanayagam^{56,198}, Kevin Sandow²³, Naveed Sattar¹⁹⁹, Annette Schürmann^{200,201}, Jinxiu Shi²⁰², Heather M Stringham^{43,42}, Kent D. Taylor²³, Tanya M. Teslovich²⁰³, Betina Thuesen¹⁷⁹, Paul RHJ Timmers^{80,204}, Elena Tremoli¹³⁵, Michael Y Tsai²⁰⁵, Andre Uitterlinden¹⁹⁶, Rob M van Dam^{41,181,206}, Diana van Heemst⁹⁷, Astrid van Hylckama Vlieg¹⁹, Jana V Van Vliet-Ostaptchouk³⁶, Jagadish Vangipurapu²⁰⁷, Henrik Vestergaard^{48,208}, Tao Wang¹⁹³, Ko Willems van Dijk^{209,210,211}, Tatijana Zemunik²¹², Goncalo R Abecasis⁴³, Linda S. Adair^{147,213}, Carlos Alberto Aguilar-

Salinas^{214,215,216}, Marta E Alarcón-Riquelme^{217,218}, Ping An²¹⁹, Larissa Aviles-Santa²²⁰, Diane M
 Becker²²¹, Lawrence J Beilin²²², Sven Bergmann^{103,104,223}, Hans Bisgaard¹⁶, Corri Black²²⁴, Michael
 Boehnke^{43,42}, Eric Boerwinkle^{225,226}, Bernhard O Böhm^{227,228}, Klaus Bønnelykke¹⁶, D I. Boomsma^{27,28},
 Erwin P. Bottinger^{39,229,230}, Thomas A Buchanan^{231,232,126}, Mickaël Canouil^{233,234}, Mark J Caulfield^{52,53},
 John C. Chambers^{86,45,46,235,236}, Daniel I. Chasman^{69,237}, Yii-Der Ida Chen²³, Ching-Yu Cheng^{56,198}, Francis
 S. Collins¹³⁹, Adolfo Correa²³⁸, Francesco Cucca⁹⁸, H. Janaka de Silva²³⁹, George Dedoussis²⁴⁰, Sölve
 Elmståhl²⁴¹, Michele K. Evans²⁴², Ele Ferrannini²⁴³, Luigi Ferrucci²⁴⁴, Jose C Florez^{245,246,107}, Paul W
 Franks^{89,247}, Timothy M Frayling¹, Philippe Froguel^{233,234,248}, Bruna Gigante²⁴⁹, Mark O. Goodarzi²⁵⁰,
 Penny Gordon-Larsen^{147,213}, Harald Grallert^{92,93}, Niels Grarup⁴⁸, Sameline Grimsgaard¹²⁷, Leif
 Groop^{251,252}, Vilmundur Gudnason^{110,253}, Xiuqing Guo²³, Anders Hamsten¹¹⁴, Torben Hansen⁴⁸,
 Caroline Hayward²⁰⁴, Susan R. Heckbert²⁵⁴, Bernardo L Horta⁷², Wei Huang²⁰², Erik Ingelsson²⁵⁵,
 Pankow S James²⁵⁶, Marjo-Ritta Jarvelin^{257,258,259,260}, Jost B Jonas^{261,262,263}, J. Wouter Jukema^{116,264},
 Pontiano Kaleebu²⁶⁵, Robert Kaplan^{193,195}, Sharon L.R. Kardia⁴⁹, Norihiro Kato¹¹⁵, Sirkka M. Keinänen-
 Kiukaanniemi^{266,267}, Bong-Jo Kim⁷⁸, Mika Kivimäki²⁶⁸, Heikki A. Koistinen^{269,270,271}, Jaspal S.
 Kooner^{46,235,236,272}, Antje Körner¹²², Peter Kovacs^{138,273}, Diana Kuh¹²⁸, Meena Kumari²⁷⁴, Zoltan
 Kutalik^{275,104}, Markku Laakso¹⁶⁹, Timo A. Lakka^{276,277,278}, Lenore J Launer⁶⁰, Karin Leander²⁷⁹, Huaixing
 Li²⁹, Xu Lin²⁹, Lars Lind²⁸⁰, Cecilia Lindgren^{12,281,282}, Simin Liu²⁰, Ruth J.F. Loos^{39,99}, Patrik KE
 Magnusson²⁸³, Anubha Mahajan¹², Andres Metspalu¹⁵, Dennis O Mook-Kanamori^{19,284}, Trevor A
 Mori²²², Patricia B Munroe^{52,53}, Inger Njølstad¹²⁷, Jeffrey R O'Connell⁹⁴, Albertine J Oldehinkel¹⁵³, Ken
 K Ong⁹, Sandosh Padmanabhan²⁸⁵, Colin N.A. Palmer²⁸⁶, Nicholette D Palmer¹⁴¹, Oluf Pedersen⁴⁸,
 Craig E Pennell⁴⁴, David J Porteous^{142,287}, Peter P. Pramstaller⁹⁶, Michael A. Province²¹⁹, Bruce M.
 Psaty^{50,254,288}, Lu Qi²⁸⁹, Leslie J. Raffel²⁹⁰, Rainer Rauramaa²⁷⁸, Susan Redline^{54,55}, Paul M Ridker^{69,291},
 Frits R. Rosendaal¹⁹, Timo E. Saaristo^{292,293}, Manjinder Sandhu²⁹⁴, Jouko Saramies²⁹⁵, Neil
 Schneiderman²⁹⁶, Peter Schwarz^{140,297,201}, Laura J. Scott^{43,42}, Elizabeth Selvin³⁸, Peter Sever²⁷², Xiao-ou
 Shu⁸⁷, P Eline Slagboom¹¹⁷, Kerrin S Small⁹⁰, Blair H Smith²⁹⁸, Harold Snieder³⁶, Tamar Sofer^{299,246},
 Thorkild I.A. Sørensen^{48,300,7,8}, Tim D Spector⁹⁰, Alice Stanton³⁰¹, Claire J Steves^{90,302}, Michael
 Stumvoll¹³⁸, Liang Sun²⁹, Yasuharu Tabara⁷⁹, E Shyong Tai^{181,41,303}, Nicholas J Timpson^{7,8}, Anke
 Tönjes¹³⁸, Jaakko Tuomilehto^{304,305,306}, Teresa Tusie^{77,307}, Matti Uusitupa³⁰⁸, Pim van der Harst^{120,26},
 Cornelia van Duijn^{85,62}, Veronique Vitart²⁰⁴, Peter Vollenweider³⁰⁹, Tanja GM Vrijkotte¹²⁹, Lynne E
 Wagenknecht³¹⁰, Mark Walker³¹¹, Ya X Wang²⁶², Nick J Wareham⁹, Richard M Watanabe^{125,232,126},
 Hugh Watkins^{152,12}, Wen B Wei³¹², Ananda R Wickremasinghe³¹³, Gonneke Willemsen^{27,28}, James F
 Wilson^{80,204}, Tien-Yin Wong^{56,198}, Jer-Yuarn Wu⁵⁸, Anny H Xiang³¹⁴, Lisa R Yanek²²¹, Loïc Yengo³¹⁵,
 Mitsuhiro Yokota³¹⁶, Eleftheria Zeggini^{111,317,318}, Wei Zheng⁸⁷, Alan B Zonderman⁶⁰, Jerome I Rotter²³,
 Anna L Gloyn^{11,12,187,319}, Mark I. McCarthy^{11,320,187,12@}, Josée Dupuis¹⁸, James B Meigs^{321,246,107}, Robert A
 Scott⁹, Inga Prokopenko^{30,24}, Aaron Leong^{322,323,237}, Ching-Ti Liu¹⁸, Stephen CJ Parker^{6,324#}, Karen L.
 Mohlke^{3#}, Claudia Langenberg^{9#}, Eleanor Wheeler^{2,9#}, Andrew P. Morris^{325,326,327,12#}, Inês Barroso^{1,2,9#}
 on behalf of the Meta-Analysis of Glucose and Insulin-related Traits Consortium (MAGIC)

¹Exeter Centre of Excellence for Diabetes Research (ExCEED), Genetics of Complex Traits, University
 of Exeter Medical School, University of Exeter, Exeter, UK, ²Department of Human Genetics,
 Wellcome Sanger Institute, Hinxton, Cambridge, UK, ³Department of Genetics, University of North
 Carolina, Chapel Hill, NC, USA, ⁴Department of Biostatistics and Epidemiology, University of
 Massachusetts, Amherst, MA, USA, ⁵Inserm, Univ Brest, EFS, UMR 1078, GGB, Brest, France,
⁶Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI,
 USA, ⁷MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK, ⁸Department of
 Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK, ⁹MRC
 Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK,
¹⁰Department of Biostatistics, School of Public Health, Shandong University, Jinan, Shandong, China,
¹¹Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine,
 University of Oxford, Oxford, UK, ¹²Wellcome Centre for Human Genetics, University of Oxford,
 Oxford, UK, ¹³Laboratory for Genomics of Diabetes and Metabolism, RIKEN Centre for Integrative

103 Medical Sciences, Yokohama, Japan, ¹⁴Medical Research Council Human Genetics Unit, Institute for
 104 Genetics and Molecular Medicine, Edinburgh, UK, ¹⁵Estonian Genome Center, Institute of Genomics,
 105 University of Tartu, Tartu, Estonia, ¹⁶COPSAC, Copenhagen Prospective Studies on Asthma in
 106 Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark, ¹⁷Steno
 107 Diabetes Center Copenhagen, Gentofte, Denmark, ¹⁸Department of Biostatistics, Boston University
 108 School of Public Health, Boston, MA, USA, ¹⁹Department of Clinical Epidemiology, Leiden University
 109 Medical Center, Leiden, The Netherlands, ²⁰Department of Epidemiology, Brown University School of
 110 Public Health, Brown University, Providence, RI, USA, ²¹Department of Biomedical Sciences, City
 111 University of Hong Kong, Hong Kong SAR, China, ²²Department of Electrical Engineering, City
 112 University of Hong Kong, Hong Kong SAR, China, ²³The Institute for Translational Genomics and
 113 Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at
 114 Harbor-UCLA Medical Center, Torrance, CA, USA, ²⁴Department of Metabolism, Digestion, and
 115 Reproduction, Imperial College London, London, UK, ²⁵Division of Preventive Medicine, Brigham and
 116 Women's Hospital, Boston, MA, USA, ²⁶Department of Genetics, University of Groningen, University
 117 Medical Center Groningen, Groningen, The Netherlands, ²⁷Department of Biological Psychology,
 118 Faculty of Behaviour and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam, The
 119 Netherlands, ²⁸Amsterdam Public Health Research Institute, Amsterdam Universities Medical Center,
 120 Amsterdam, The Netherlands, ²⁹CAS Key Laboratory of Nutrition, Metabolism and Food Safety,
 121 Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese
 122 Academy of Sciences, Shanghai, China, ³⁰Section of Statistical Multi-omics, Department of Clinical
 123 and Experimental Research, University of Surrey, Guildford, Surrey, UK, ³¹Department of
 124 Biostatistics, University of Washington, Seattle, WA, USA, ³²SYNLAB Academy, SYNLAB Holding
 125 Deutschland GmbH, Mannheim, Germany, ³³Clinical Institute of Medical and Chemical Laboratory
 126 Diagnostics, Medical University Graz, Graz, Austria, ³⁴Vth Department of Medicine (Nephrology,
 127 Hypertensiology, Rheumatology, Endocrinology, Diabetology), Medical Faculty Mannheim,
 128 Heidelberg University, Mannheim, Baden-Württemberg, Germany, ³⁵Department of Economics,
 129 Metropolitan Autonomous University, Mexico City, Mexico, ³⁶Department of Epidemiology,
 130 University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, ³⁷CVD
 131 Genetic Epidemiology Computational Laboratory, Gillings School of Global Public Health, University
 132 of North Carolina, Chapel Hill, NC, USA, ³⁸Department of Epidemiology, Johns Hopkins Bloomberg
 133 School of Public Health, Baltimore, MD, USA, ³⁹The Charles Bronfman Institute for Personalized
 134 Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA, ⁴⁰HPI Digital Health Center,
 135 Digital Health and Personalized Medicine, Hasso Plattner Institute, Potsdam, Germany, ⁴¹Saw Swee
 136 Hock School of Public Health, National University of Singapore and National University Health
 137 System, Singapore, Singapore, ⁴²Center for Statistical Genetics, University of Michigan, Ann Arbor,
 138 MI, USA, ⁴³Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor,
 139 MI, USA, ⁴⁴School of Medicine and Public Health, College of Health, Medicine and Wellbeing, The
 140 University of Newcastle, Newcastle, NSW, Australia, ⁴⁵Department of Epidemiology and Biostatistics,
 141 Imperial College London, London, UK, ⁴⁶Department of Cardiology, Ealing Hospital, London North
 142 West Healthcare NHS Trust, Middlesex, UK, ⁴⁷The Bioinformatics Centre, Department of Biology,
 143 University of Copenhagen, Copenhagen, Denmark, ⁴⁸Novo Nordisk Foundation Center for Basic
 144 Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen,
 145 Copenhagen, Denmark, ⁴⁹Department of Epidemiology, School of Public Health, University of
 146 Michigan, Ann Arbor, MI, USA, ⁵⁰Department of Medicine, Cardiovascular Health Research Unit,
 147 University of Washington, Seattle, WA, USA, ⁵¹Metabolism Program, Program in Medical and
 148 Population Genetics, Broad Institute, Cambridge, MA, USA, ⁵²Department of Clinical Pharmacology,
 149 William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen
 150 Mary University of London, London, UK, ⁵³NIHR Barts Cardiovascular Biomedical Research Centre,
 151 Queen Mary University of London, London, UK, ⁵⁴Department of Medicine, Sleep and Circadian
 152 Disorders, Brigham and Women's Hospital, Boston, MA, USA, ⁵⁵Department of Medicine, Sleep
 153 Medicine, Harvard Medical School, Boston, MA, USA, ⁵⁶Ocular Epidemiology, Singapore Eye Research

154 Institute, Singapore National Eye Centre, Singapore, Singapore, ⁵⁷Department of Ophthalmology,
 155 National University of Singapore and National University Health System, Singapore, Singapore,
 156 ⁵⁸Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, Taiwan, ⁵⁹Department of
 157 Epidemiology, The Herbert Wertheim School of Public Health and Human Longevity Science, UC San
 158 Diego, La Jolla, CA, USA, ⁶⁰Laboratory of Epidemiology and Population Sciences, National Institute on
 159 Aging, National Institutes of Health, Baltimore, MD, USA, ⁶¹Institute of Population Health Sciences,
 160 National Health Research Institutes, Miaoli, Taiwan, ⁶²Department of Epidemiology, Erasmus Medical
 161 Center, Rotterdam, The Netherlands, ⁶³Department of Statistics, University of North Carolina at
 162 Chapel Hill, Chapel Hill, NC, USA, ⁶⁴Institute of Cardiovascular Science, UCL, London, UK, ⁶⁵Uganda
 163 Medical Informatics Centre (UMIC), MRC/UVR and London School of Hygiene & Tropical Medicine
 164 (Uganda Research Unit), Entebbe, Uganda, ⁶⁶London School of Hygiene & Tropical Medicine, London,
 165 UK, ⁶⁷H3Africa Bioinformatics Network (H3ABioNet) Node, Centre for Genomics Research and
 166 Innovation, NABDA/FMST, Abuja, Nigeria, ⁶⁸Bioinfosol, Sevilla, Spain, ⁶⁹Division of Preventive
 167 Medicine, Brigham and Women's Hospital, Boston, MA, USA, ⁷⁰Department of Medical Sciences,
 168 Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden,
 169 ⁷¹Department of Statistics, The University of Auckland, Science Center, Auckland, New Zealand,
 170 ⁷²Postgraduate Program in Epidemiology, Federal University of Pelotas, Pelotas, RS, Brazil,
 171 ⁷³Department of Medicine, Epidemiology, Vanderbilt University Medical Center, Nashville, TN, USA,
 172 ⁷⁴Department of Epidemiology, Tulane University Obesity Research Center,, Tulane University, New
 173 Orleans, USA, ⁷⁵Department of Epidemiology and Biostatistics, School of Public Health, Peking
 174 University, Beijing, China, ⁷⁶Molecular Biology and Genomic Medicine Unit, National Council for
 175 Science and Technology, Mexico City, Mexico, ⁷⁷Molecular Biology and Genomic Medicine Unit,
 176 National Institute of Medical Sciences and Nutrition, Mexico City, Mexico, ⁷⁸Division of Genome
 177 Science, Department of Precision Medicine, National Institute of Health, Cheongju-si,
 178 Chungcheongbuk-do, South Korea, ⁷⁹Center for Genomic Medicine, Kyoto University Graduate
 179 School of Medicine, Kyoto, Japan, ⁸⁰Centre for Global Health Research, Usher Institute, University of
 180 Edinburgh, Edinburgh, Scotland, ⁸¹Centre for Cardiovascular Sciences, Queen's Medical Research
 181 Institute, University of Edinburgh, Edinburgh, Scotland, ⁸²Department of Medicine, Division of
 182 Biomedical Informatics and Personalized Medicine, University of Colorado Anschutz Medical
 183 Campus, Denver, CO, USA, ⁸³Department of Biostatistics and Data Science, Wake Forest School of
 184 Medicine, Winston-Salem, NC, USA, ⁸⁴Department of Medicine, Division of Nephrology and
 185 Hypertension, University of Utah, Salt Lake City, UT, USA, ⁸⁵Nuffield Department of Population
 186 Health, University of Oxford, Oxford, UK, ⁸⁶Lee Kong Chian School of Medicine, Nanyang
 187 Technological University, Singapore, Singapore, ⁸⁷Division of Epidemiology, Department of Medicine,
 188 Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, Nashville, TN, USA,
 189 ⁸⁸Department of Clinical Science, Center for Diabetes Research, University of Bergen, Bergen,
 190 Norway, ⁸⁹Department of Clinical Sciences, Lund University Diabetes Centre, Lund University,
 191 Malmö, Sweden, ⁹⁰Department of Twin Research and Genetic Epidemiology, School of Life Course
 192 Sciences, King's College London, London, UK, ⁹¹NIHR Biomedical Research Centre, Guy's and St
 193 Thomas' Foundation Trust, London, UK, ⁹²Institute of Epidemiology, Research Unit of Molecular
 194 Epidemiology, Helmholtz Zentrum München Research Center for Environmental Health, Neuherberg,
 195 Bavaria, Germany, ⁹³German Center for Diabetes Research (DZD), Neuherberg, Bavaria, Germany,
 196 ⁹⁴Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of
 197 Maryland School of Medicine, Baltimore, MD, USA, ⁹⁵Public Health Informatics Unit, Department of
 198 Integrated Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁹⁶Institute for
 199 Biomedicine, Eurac Research, Bolzano, BZ, Italy, ⁹⁷Department of Internal Medicine, Section of
 200 Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands, ⁹⁸Istituto di
 201 Ricerca Genetica e Biomedica (IRGB), Consiglio Nazionale delle Ricerche (CNR), Monserrato, Italy,
 202 ⁹⁹The Mindich Child Health and Development Institute for Personalized Medicine, Icahn School of
 203 Medicine at Mount Sinai, New York, NY, USA, ¹⁰⁰Department of Preventive Medicine, Northwestern
 204 University Feinberg School of Medicine, Chicago, IL, USA, ¹⁰¹Center for Public Health Genomics,

205 University of Virginia, Charlottesville, VA, USA, ¹⁰²Department of Public Health Sciences, University of
 206 Virginia, Charlottesville, VA, USA, ¹⁰³Department of Computational Biology, University of Lausanne,
 207 Lausanne, Switzerland, ¹⁰⁴Swiss Institute of Bioinformatics, Lausanne, Switzerland, ¹⁰⁵Center for
 208 Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA,
 209 ¹⁰⁶Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital,
 210 Boston, MA, USA, ¹⁰⁷Program in Medical and Population Genetics,, Broad Institute, Cambridge, MA,
 211 USA, ¹⁰⁸Department of Cell and Molecular Biology., National Bioinformatics Infrastructure Sweden,,
 212 Science for Life Laboratory, Uppsala University, Uppsala, Sweden, ¹⁰⁹Department of Biostatistics,
 213 University of Michigan, Ann Arbor, MI, USA, ¹¹⁰Icelandic Heart Association, Kopavogur, Iceland,
 214 ¹¹¹Institute of Translational Genomics, Helmholtz Zentrum München – German Research Center for
 215 Environmental Health, Neuherberg, Germany, ¹¹²Wellcome Sanger Institute, Hinxton, Cambridge,
 216 UK, ¹¹³Institute of Health and Wellbeing, University of Glasgow, Glasgow, Glasgow, UK,
 217 ¹¹⁴Department of Medicine Solna, Cardiovascular medicine, Karolinska Institutet, Stockholm,
 218 Sweden, ¹¹⁵National Center for Global Health and Medicine, Tokyo, Japan, ¹¹⁶Department of
 219 Cardiology, Leiden University Medical Center, Leiden, The Netherlands, ¹¹⁷Department of Biomedical
 220 Data Sciences, Molecular Epidemiology, Leiden University Medical Center, Leiden, The Netherlands,
 221 ¹¹⁸Department of Pattern Recognition & Bioinformatics, Delft University of Technology, Delft, The
 222 Netherlands, ¹¹⁹Department of Biomedical Data Sciences, Leiden Computational Biology Center,
 223 Leiden University Medical Center, Leiden, The Netherlands, ¹²⁰Department of Cardiology, University
 224 of Groningen, University Medical Center Groningen, Groningen, The Netherlands, ¹²¹Genomics plc,
 225 Oxford, UK, ¹²²Center of Pediatric Research, University Children’s Hospital Leipzig, University of
 226 Leipzig Medical Center, Leipzig, Germany, ¹²³Department of Epidemiology and Biostatistics, School of
 227 Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan,
 228 China, ¹²⁴Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore,
 229 Singapore, ¹²⁵Department of Preventive Medicine, Keck School of Medicine of USC, Los Angeles, CA,
 230 USA, ¹²⁶USC Diabetes and Obesity Research Institute, Keck School of Medicine of USC, Los Angeles,
 231 CA, USA, ¹²⁷Department of Community Medicine, Faculty of Health Sciences, UIT the Arctic
 232 University of Norway, Tromsø, Norway, ¹²⁸MRC Unit for Lifelong Health & Ageing at UCL, London,
 233 UK, ¹²⁹Department of Public Health, Amsterdam Public Health Research Institute, Amsterdam
 234 Universities Medical Center, Amsterdam, The Netherlands, ¹³⁰Department of Clinical Epidemiology,
 235 Biostatistics, and Bioinformatics, Amsterdam Public Health Research Institute, Amsterdam
 236 Universities Medical Center, Amsterdam, The Netherlands, ¹³¹Department of Public Health and
 237 Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK, ¹³²Department of
 238 Nutrition, Exercise, and Sports, Faculty of Science, University of Copenhagen, Copenhagen,
 239 Denmark, ¹³³Department of Internal Medicine, University of Groningen, University Medical Center
 240 Groningen, Groningen, The Netherlands, ¹³⁴Department of Medical Biotechnology and Translational
 241 Medicine, University of Milan, Milan, Milan, Italy, ¹³⁵Centro Cardiologico Monzino, IRCCS, Milan,
 242 Italy, ¹³⁶Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA,
 243 ¹³⁷Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest
 244 School of Medicine, Winston-Salem, NC, USA, ¹³⁸Medical Department III – Endocrinology,
 245 Nephrology, Rheumatology, University of Leipzig Medical Center, Leipzig, Germany, ¹³⁹Medical
 246 Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National
 247 Institutes of Health, Bethesda, MD, USA, ¹⁴⁰Department for Prevention and Care of Diabetes, Faculty
 248 of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, ¹⁴¹Department
 249 of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC, USA, ¹⁴²Centre for Genomic
 250 and Experimental Medicine, Institute of Genetics & Molecular Medicine, University of Edinburgh,
 251 Western General Hospital, Edinburgh, UK, ¹⁴³Usher Institute, University of Edinburgh, Edinburgh, UK,
 252 ¹⁴⁴Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ¹⁴⁵Graduate
 253 Institute of Medical Genomics and Proteomics, National Taiwan University, Taipei, Taiwan,
 254 ¹⁴⁶Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, ¹⁴⁷Department of Nutrition,
 255 Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA,

¹⁴⁸Department of Population Science and Experimental Medicine, Institute of Cardiovascular Science,
 University College London, London, UK, ¹⁴⁹Department of Nutrition and Dietetics, School of Health
 Science and Education, Harokopio University of Athens, Athens, Greece, ¹⁵⁰Department of Medicine
 Solna, Cardiovascular medicine, Stockholm, Sweden, ¹⁵¹Department of Epidemiology, Shanghai
 Cancer Institute, Shanghai, China, ¹⁵²Division of Cardiovascular Medicine, Radcliffe Department of
 Medicine, University of Oxford, Oxford, UK, ¹⁵³Department of Psychiatry, Interdisciplinary Center
 Psychopathy and Emotion Regulation, University of Groningen, University Medical Center
 Groningen, Groningen, The Netherlands, ¹⁵⁴Institute for Clinical Diabetology, German Diabetes
 Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf,
 Germany, ¹⁵⁵Division of Endocrinology and Diabetology, Medical Faculty, Heinrich Heine University
 Düsseldorf, Düsseldorf, Germany, ¹⁵⁶German Center for Diabetes Research (DZD), Düsseldorf,
 Germany, ¹⁵⁷Internal Medicine, Endocrine & Metabolism, Tri-Service General Hospital, Taipei,
 Taiwan, ¹⁵⁸School of Medicine, National Defense Medical Center, Taipei, Taiwan, ¹⁵⁹Internal
 Medicine, Endocrinology, Diabetes & Metabolism, Diabetes and Metabolism Research Center, The
 Ohio State University Wexner Medical Center, Columbus, OH, USA, ¹⁶⁰Department of Environmental
 and Preventive Medicine, Jichi Medical University School of Medicine, Shimotsuke, Japan,
¹⁶¹Department of Anti-aging Medicine, Ehime University Graduate School of Medicine, Toon, Japan,
¹⁶²National Institute of Public Health, University of Southern Denmark, Odense, Denmark,
¹⁶³Department of Medicine, Endocrinology, Diabetes & Metabolism, Johns Hopkins University School
 of Medicine, Baltimore, MD, USA, ¹⁶⁴Clinical Diabetes, Endocrinology & Metabolism, Translational
 Research & Cellular Therapeutics, Beckman Research Institute of the City of Hope, Duarte, CA, USA,
¹⁶⁵Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Suita, Japan,
¹⁶⁶Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine,
 Suita, Japan, ¹⁶⁷Department of Public Health, University of Split School of Medicine, Split, Croatia,
¹⁶⁸Institute of Biomedicine, Bioinformatics Center, University of Eastern Finland, Kuopio, Finland,
¹⁶⁹Department of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio,
 Finland, ¹⁷⁰MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK, ¹⁷¹USC-Office
 of Population Studies Foundation, University of San Carlos, Cebu City, Philippines, ¹⁷²Department of
 Anthropology, Sociology and History, University of San Carlos, Cebu City, Philippines, ¹⁷³State Key
 Laboratory of Oncogene and Related Genes & Department of Epidemiology, Shanghai Cancer
 Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China,
¹⁷⁴Groningen, The Netherlands, ¹⁷⁵Internal Medicine, Endocrine & Metabolism, Taichung Veterans
 General Hospital, Taichung, Taiwan, ¹⁷⁶Center for Geriatrics and Gerontology,, Taichung Veterans
 General Hospital, Taichung, Taiwan, ¹⁷⁷National Defense Medical Center, National Yang-Ming
 University, Taipei, Taiwan, ¹⁷⁸Diabetes Prevention Unit, National Institute for Health and Welfare,
 Helsinki, Finland, ¹⁷⁹Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg
 Hospital, Copenhagen, Denmark, ¹⁸⁰Department of Clinical Medicine, Faculty of Health and Medical
 Sciences, University of Copenhagen, Copenhagen, Denmark, ¹⁸¹Yong Loo Lin School of Medicine,
 National University of Singapore and National University Health System, Singapore, Singapore,
¹⁸²Department of Medicine, University of Texas Health Sciences Center, San Antonio, TX, USA,
¹⁸³Department of Internal Medicine, Aichi Gakuin University School of Dentistry, Nagoya, Japan,
¹⁸⁴Department of Diabetes, Diabetes, & Nutritional Sciences, James Black Centre, King's College
 London, London, UK, ¹⁸⁵Department of Functional Pathology, Shimane University School of
 Medicine, Izumo, Japan, ¹⁸⁶Department of Medicine and Pharmacology, New York Medical College
 School of Medicine, Valhalla, NY, USA, ¹⁸⁷Oxford NIHR Biomedical Research Centre, Oxford University
 Hospitals NHS Foundation Trust, Oxford, UK, ¹⁸⁸Colorado School of Public Health, University of
 Colorado Anschutz Medical Campus, Aurora, CO, USA, ¹⁸⁹Department of Geriatric Medicine and
 Neurology, Ehime University Graduate School of Medicine, Toon, Japan, ¹⁹⁰Institute of Epidemiology,
 Helmholtz Zentrum München Research Center for Environmental Health, Neuherberg, Bavaria,
 Germany, ¹⁹¹Institute for Medical Information Processing, Biometry, and Epidemiology, Ludwig-
 Maximilians University Munich, Munich, Bavaria, Germany, ¹⁹²Gen-info Ltd, Zagreb, Croatia,

¹⁹³Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA, ¹⁹⁴Genetics and Pharmacogenomics, Merck Sharp & Dohme Corp., Kenilworth, NJ, USA, ¹⁹⁵Department of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, ¹⁹⁶Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands, ¹⁹⁷Centre for Global Health, The Usher Institute, University of Edinburgh, Edinburgh, UK, ¹⁹⁸Ophthalmology & Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, Singapore, Singapore, ¹⁹⁹BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK, ²⁰⁰Department of Experimental Diabetology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany, ²⁰¹German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany, ²⁰²Department of Genetics, Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center at Shanghai (CHGC) and Shanghai Academy of Science & Technology (SAST), Shanghai, China, ²⁰³Sarepta Therapeutics, Cambridge, Massachusetts, USA, ²⁰⁴Medical Research Council Human Genetics Unit, Institute for Genetics and Cancer, University of Edinburgh, Edinburgh, UK, ²⁰⁵Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA, ²⁰⁶Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA, ²⁰⁷Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland, ²⁰⁸Department of Medicine, Bornholms Hospital, Rønne, Denmark, ²⁰⁹Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands, ²¹⁰Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands, ²¹¹Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands, ²¹²Department of Human Biology, University of Split School of Medicine, Split, Croatia, ²¹³Carolina Population Center, University of North Carolina, Chapel Hill, NC, USA, ²¹⁴Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ²¹⁵Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición and Tec Salud, Mexico City, Mexico, ²¹⁶Instituto Tecnológico y de Estudios Superiores de Monterrey Tec Salud, Mexico City, Mexico, ²¹⁷Department of Medical Genomics, Pfizer/University of Granada/Andalusian Government Center for Genomics and Oncological Research (GENYO), Granada, Spain, ²¹⁸Institute for Environmental Medicine, Chronic Inflammatory Diseases, Karolinska Institutet, Solna, Sweden, ²¹⁹Department of Genetics, Division of Statistical Genomics, Washington University School of Medicine, St. Louis, MO, USA, ²²⁰Clinical and Health Services Research, National Institute on Minority Health and Health Disparities, Bethesda, MD, USA, ²²¹Department of Medicine, General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA, ²²²Medical School, Royal Perth Hospital Unit, University of Western Australia, Perth, WA, Australia, ²²³Department of Integrative Biomedical Sciences, University of Cape Town, Cape Town, South Africa, ²²⁴Aberdeen Centre for Health Data Science, 1:042 Polwarth Building,, School of Medicine, Medical, Science and Nutrition, University of Aberdeen, Foresterhill, Aberdeen, UK, ²²⁵Human Genetics Center, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, USA, ²²⁶Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA, ²²⁷Division of Endocrinology and Diabetes, Graduate School of Molecular Endocrinology and Diabetes, University of Ulm, Ulm, Baden-Württemberg, Germany, ²²⁸LKC School of Medicine, Nanyang Technological University, Singapore and Imperial College London, UK, Singapore, Singapore, ²²⁹Hasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY, USA, ²³⁰Digital Health Center, Hasso Plattner Institut, University Potsdam, Potsdam, Germany, ²³¹Department of Medicine, Keck School of Medicine of USC, Los Angeles, CA, USA, ²³²Department of Physiology and Neuroscience, Keck School of Medicine of USC, Los Angeles, CA, USA, ²³³INSERM UMR 1283 / CNRS UMR 8199, European Institute for Diabetes (EGID), Université de Lille, Lille, France, ²³⁴INSERM UMR 1283 / CNRS UMR 8199, European Institute for Diabetes (EGID), Institut Pasteur de Lille, Lille, France, ²³⁵Imperial College Healthcare NHS Trust, Imperial College London, London, UK, ²³⁶MRC-PHE Centre for Environment and Health, Imperial College London, London, UK, ²³⁷Harvard Medical School, Boston,

358 MA, USA, ²³⁸Department of Medicine, Jackson Heart Study, University of Mississippi Medical Center,
 359 Jackson, MS, USA, ²³⁹Department of Medicine, Faculty of Medicine, University of Kelaniya, Ragama,
 360 Sri Lanka, ²⁴⁰Department of Nutrition and Dietetics, School of Health Science and Education,
 361 Harokopio University of Athens, Kallithea, Greece, ²⁴¹Department of Clinical Sciences, Lund
 362 University, Malmö, Sweden, ²⁴²Laboratory of Epidemiology and Population Sciences, National
 363 Institute on Aging Intramural Research Program, National Institutes of Health, Baltimore, MD, USA,
 364 ²⁴³CNR Institute of Clinical Physiology, Pisa, Italy, ²⁴⁴Intramural Research Program, National Institute
 365 of Aging, Baltimore, MD, USA, ²⁴⁵Diabetes Unit and Center for Genomic Medicine, Massachusetts
 366 General Hospital, Boston, MA, USA, ²⁴⁶Department of Medicine, Harvard Medical School, Boston,
 367 MA, USA, ²⁴⁷Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden,
 368 ²⁴⁸Department of Genomics of Common Disease, Imperial College London, London, UK,
 369 ²⁴⁹Department of Medicine, Cardiovascular medicine, Karolinska Institutet, Stockholm, Sweden,
 370 ²⁵⁰Department of Medicine, Division of Endocrinology, Diabetes & Metabolism, Cedars-Sinai Medical
 371 Center, Los Angeles, CA, USA, ²⁵¹Diabetes Centre, Lund University, Sweden, ²⁵²Finnish Institute of
 372 Molecular Medicine, Helsinki University, Helsinki, Finland, ²⁵³Faculty of Medicine, School of health
 373 sciences, University of Iceland, Reykjavik, Iceland, ²⁵⁴Department of Epidemiology, Cardiovascular
 374 Health Research Unit, University of Washington, Seattle, WA, USA, ²⁵⁵Department of Medicine,
 375 Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford University,
 376 Stanford, CA, USA, ²⁵⁶Division of Epidemiology and Community Health, University of Minnesota,
 377 Minneapolis, MN, USA, ²⁵⁷Department of Epidemiology and Biostatistics, MRC-PHE Centre for
 378 Environment and Health, School of Public Health, Imperial College London, London, UK, ²⁵⁸Center for
 379 Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland, ²⁵⁹Unit of
 380 Primary Health Care, Oulu University Hospital, OYS, Oulu, Finland, ²⁶⁰Department of Life Sciences,
 381 College of Health and Life Sciences, Brunel University London, London, UK, ²⁶¹Department of
 382 Ophthalmology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, ²⁶²Beijing
 383 Institute of Ophthalmology, Beijing Ophthalmology and Visual Science Key Lab, Beijing Tongren Eye
 384 Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China, ²⁶³Institute of Molecular
 385 and Clinical Ophthalmology Basel IOB, Basel, Switzerland, ²⁶⁴Netherlands Heart Institute, Utrecht,
 386 The Netherlands, ²⁶⁵MRC/UVRI and LSHTM (Uganda Research Unit), Entebbe, Uganda, ²⁶⁶Faculty of
 387 Medicine, Institute of Health Sciences, University of Oulu, Oulu, Finland, ²⁶⁷Unit of General Practice,
 388 Oulu University Hospital, Oulu, Finland, ²⁶⁸Department of Epidemiology and Public Health, UCL,
 389 London, UK, ²⁶⁹Department of Public Health Solutions, Finnish Institute for Health and Welfare,
 390 Helsinki, Finland, ²⁷⁰Department of Medicine, University of Helsinki and Helsinki University Central
 391 Hospital, Helsinki, Finland, ²⁷¹Minerva Foundation Institute for Medical Research, Helsinki, Finland,
 392 ²⁷²National Heart and Lung Institute, Imperial College London, London, UK, ²⁷³IFB Adiposity Diseases,
 393 University of Leipzig Medical Center, Leipzig, Germany, ²⁷⁴Institute for Social and Economic Research,
 394 University of Essex, Colchester, UK, ²⁷⁵University Institute of Primary Care and Public Health, Division
 395 of Biostatistics, University of Lausanne, Lausanne, Switzerland, ²⁷⁶Institute of Biomedicine, School of
 396 Medicine, University of Eastern Finland, Finland, ²⁷⁷Department of Clinical Physiology and Nuclear
 397 Medicine, Kuopio University Hospital, Kuopio, Finland, ²⁷⁸Foundation for Research in Health Exercise
 398 and Nutrition, Kuopio Research Institute of Exercise Medicine, Kuopio, Finland, ²⁷⁹Institute of
 399 Environmental Medicine, Cardiovascular and Nutritional Epidemiology, Karolinska Institutet,
 400 Stockholm, Sweden, ²⁸⁰Department of Medical Sciences, Uppsala, Sweden, ²⁸¹Big Data Institute,
 401 Nuffield Department of Medicine, University of Oxford, Oxford, UK, ²⁸²Nuffield Department of
 402 Women's and Reproductive Health, University of Oxford, Oxford, UK, ²⁸³Department of Medical
 403 Epidemiology and Biostatistics and the Swedish Twin Registry, Karolinska Institutet, Stockholm,
 404 Sweden, ²⁸⁴Department of Public Health and Primary Care, Leiden University Medical Center, Leiden,
 405 The Netherlands, ²⁸⁵Institute of Cardiovascular and Medical Sciences, University of Glasgow,
 406 Glasgow, UK, ²⁸⁶Division of Population Health and Genomics, School of Medicine, University of
 407 Dundee, Ninewells Hospital and Medical School, Dundee, UK, ²⁸⁷Centre for Cognitive Ageing and
 408 Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK, ²⁸⁸Department of Health Services,

Cardiovascular Health Research Unit, University of Washington, Seattle, WA, USA, ²⁸⁹Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA, ²⁹⁰Department of Pediatrics, Genetic and Genomic medicine, University of California, Irvine, Irvine, CA, USA, ²⁹¹Havard Medical School, Boston, MA, USA, ²⁹²Tampere, Finnish Diabetes Association, Tampere, Finland, ²⁹³Pirkanmaa Hospital District, Tampere, Finland, ²⁹⁴Department of Medicine, University of Cambridge, Cambridge, UK, ²⁹⁵South Karelia Central Hospital, Lappeenranta, Finland, ²⁹⁶Department of Psychology, University of Miami, Miami, FL, USA, ²⁹⁷Paul Langerhans Institute Dresden of the Helmholtz Center Munich, University Hospital and Faculty of Medicine, Dresden, Germany, ²⁹⁸Division of Population Health and Genomics, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK, ²⁹⁹Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, Boston, MA, USA, ³⁰⁰Department of Public Health, Section of Epidemiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, ³⁰¹Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland, ³⁰²Department of Aging and Health, Guy's and St Thomas' Foundation Trust, London, UK, ³⁰³Cardiovascular and Metabolic Disease Signature Research Program, Duke-NUS Medical School, Singapore, Singapore, ³⁰⁴Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland, ³⁰⁵Department of Public Health, University of Helsinki, Helsinki, Finland, ³⁰⁶Saudi Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia, ³⁰⁷Department of Genomic Medicine and Environmental Toxicology, Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ³⁰⁸Department of Public Health and Clinical Nutrition, University of Eastern Finland, Finland, ³⁰⁹Department of Medicine, Internal Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland, ³¹⁰Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA, ³¹¹Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK, ³¹²Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab, Beijing Tongren Hospital, Capital Medical University, Beijing, China, China, ³¹³Department of Public Health, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka, ³¹⁴Department of Research and Evaluation, Kaiser Permanente of Southern California, Pasadena, CA, USA, ³¹⁵Institute for Molecular Bioscience, The University of Queensland, Queensland, Australia, ³¹⁶Kurume University School of Medicine, Japan, ³¹⁷Wellcome Sanger Institute, Hinxton, UK, ³¹⁸TUM School of Medicine, Technical University of Munich and Klinikum Rechts der Isar, Munich, Germany, ³¹⁹Department of Pediatrics, Division of Endocrinology, Stanford School of Medicine, Stanford, CA, USA, ³²⁰Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK, ³²¹Department of Medicine, Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA, ³²²Department of Medicine, General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA, ³²³Department of Medicine, Diabetes Unit and Endocrine Unit, Massachusetts General Hospital, Boston, MA, USA, ³²⁴Department of Human Genetics, University of Michigan, Ann Arbor, MI, USA, ³²⁵Centre for Genetics and Genomics Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, UK, ³²⁶Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, UK, ³²⁷Department of Biostatistics, University of Liverpool, Liverpool, UK

Denote shared authorship contributions

@ Current address: Genentech, South San Francisco, CA

***Corresponding author:** Inês Barroso, Exeter Centre of Excellence for Diabetes Research (EXCEED), Exeter Medical School, University of Exeter, Exeter, UK, +44 1392 408221, ines.barroso@exeter.ac.uk

Abstract

Glycemic traits are used to diagnose and monitor type 2 diabetes, and cardiometabolic health. To date, most genetic studies of glycemic traits have focused on individuals of European ancestry. Here, we aggregated genome-wide association studies in up to 281,416 individuals without diabetes (30% non-European ancestry) with fasting glucose, 2h-glucose post-challenge, glycated hemoglobin, and fasting insulin data. Trans-ancestry and single-ancestry meta-analyses identified 242 loci (99 novel; $P < 5 \times 10^{-8}$), 80% with no significant evidence of between-ancestry heterogeneity. Analyses restricted to European ancestry individuals with equivalent sample size would have led to 24 fewer new loci. Compared to single-ancestry, equivalent sized trans-ancestry fine-mapping reduced the number of estimated variants in 99% credible sets by a median of 37.5%. Genomic feature, gene-expression and gene-set analyses revealed distinct biological signatures for each trait, highlighting different underlying biological pathways. Our results increase understanding of diabetes pathophysiology by use of trans-ancestry studies for improved power and resolution.

Fasting glucose (FG), 2h-glucose post-challenge (2hGlu), and glycated hemoglobin (HbA1c) are glycemic traits used to diagnose diabetes¹. In addition, HbA1c is the most commonly used biomarker to monitor glucose control in patients with diabetes. Fasting insulin (FI) reflects a combination of insulin secretion and insulin resistance, both components of type 2 diabetes (T2D), and insulin clearance². Collectively, all four glycemic traits can be useful to better understand T2D pathophysiology³⁻⁵ and cardiometabolic outcomes⁶.

To date, genome-wide association studies (GWAS) and analysis of Metabochip and exome arrays have identified >120 loci associated with glycemic traits in individuals without diabetes⁷⁻¹⁵. However, despite considerable differences in the prevalence of T2D risk factors across ancestries¹⁶⁻¹⁸, most glycemic trait GWAS have insufficient representation of individuals of non-European ancestry and limited resolution for fine-mapping of causal variants and effector transcript identification. Here, we present large-scale trans-ancestry meta-analyses of GWAS for four glycemic traits in individuals without diabetes. We aimed to identify additional glycemic trait-associated loci; investigate the portability of loci and genetic scores across ancestries; leverage differences in effect allele frequency (EAF), effect size, and linkage disequilibrium (LD) across diverse populations to conduct fine-mapping and aid causal variant/effector transcript identification; and compare the genetic architecture of glycemic traits to further elucidate underlying biology and T2D pathophysiology.

Results

Study design and definitions

To identify loci associated with glycemic traits FG, 2hGlu, FI, and HbA1c, we aggregated GWAS in up to 281,416 individuals without diabetes, ~30% of whom were of non-European ancestry [13% East Asian, 7% Hispanic, 6% African-American, 3% South Asian, and 2% sub-Saharan African (Ugandan data only available for HbA1c)]. Each cohort imputed data to the 1000 Genomes Project reference panel¹⁹ (phase 1 v3, March 2012, or later; **Methods, Supplementary Table 1, Extended Data Figure 1, Supplementary Note**). Up to ~49.3 million variants were directly genotyped or imputed, with between 38.6 million (2hGlu) and 43.5 million variants (HbA1c) available for analysis after exclusions based on minor allele count (MAC < 3) and imputation quality (imputation r^2 or INFO score < 0.40) in each cohort. FG, 2hGlu and FI analyses were adjusted for BMI¹⁵ but for simplicity they are abbreviated as FG, 2hGlu and FI (**Methods**).

We first performed trait-specific fixed-effect meta-analyses *within* each ancestry using METAL²⁰. We defined “single-ancestry lead” variants as the strongest trait-associated variants ($P < 5 \times 10^{-8}$) within a 1Mb region in an ancestry (**Table 1**). Within each ancestry and each autosome, we used approximate conditional analyses in GCTA^{21,22}, to identify “single-ancestry index variants” ($P < 5 \times 10^{-8}$) that exert conditionally distinct effects on the trait (**Table 1, Methods, Supplementary Note**). This approach identified 124 FG, 15 2hGlu, 48 FI and 139 HbA1c variants that were significant in at least one ancestry (**Supplementary Table 2**).

Next, we conducted trait-specific *trans-ancestry* meta-analyses using MANTRA (**Methods, Supplementary Table 1, Supplementary Note**) to identify genome-wide significant “trans-ancestry lead variants”, defined as the most significant trait-associated variant across all ancestries ($\log_{10}$ Bayes Factor [BF] > 6, equivalent to $P < 5 \times 10^{-8}$)²³ (**Table 1, Methods**). Here, we present trans-ancestry results as our primary results (**Supplementary Table 2**).

Causal variants are expected to affect related glycemic traits and may be shared across ancestries. Therefore, we combined all single-ancestry lead variants, single-ancestry index variants, and/or trans-ancestry lead variants (for any trait) mapping within 500Kb of each other, into a single “trans-ancestry locus” bounded by 500Kb flanking sequences (**Table 1, Extended Data Figure 2**). As defined,

a trans-ancestry locus may contain multiple causal variants affecting one or more glycemic traits, exerting their effect in one or more ancestry.

Glycemic trait locus discovery

Trans-ancestry meta-analyses identified 235 trans-ancestry loci, of which 59 contained lead variants for more than one trait. In addition, we identified seven “single-ancestry loci” that did not contain any trans-ancestry lead variants (**Table 1, Supplementary Table 2**). Of the 242 combined loci, 99 (including 6 of the 7 single-ancestry) had not been previously associated with any of the four glycemic traits or with T2D, at the time of analysis (**Figure 1, Supplementary Table 3, Supplementary note**). However, based on recent East Asian and trans-ancestry T2D GWAS meta-analyses²³⁻²⁷, the lead variants at 27/99 novel glycemic trait loci have strong evidence of association with T2D ($P < 10^{-4}$; 13 loci with $P < 5 \times 10^{-8}$), suggesting they are also important in T2D pathophysiology (**Supplementary Tables 2 and 4**).

Of the six single-ancestry novel loci, three were unique to non-European ancestry individuals (**Supplementary Table 3**). An African American association for FI (lead variant rs12056334) near *LOC100128993* (an uncharacterized RNA gene; **Supplementary Note**). An African American association for FG (lead variant rs61909476) near *ETS1* and a Hispanic association for FG (lead variant rs12315677) within *PIK3C2G* (**Supplementary Table 3**). Despite broadly similar EAF across ancestries, rs61909476 was only significantly associated with FG in African American individuals (EAF ~7%, $b = 0.0812$ mmol/l, $SE = 0.01$ mmol/l, $P = 3.9 \times 10^{-8}$ vs EAF 10-17%, $b = 0.002$ mmol/l, $se = 0.003$ - 0.017 mmol/l, $P = 0.44$ - 0.95 in all other ancestries, **Supplementary table 2, Supplementary note**). The nearest gene, *ETS1*, encodes a transcription factor that localizes to insulin-positive cells, and its overexpression decreases glucose-stimulated insulin secretion in mouse islets²⁸. Located within the *PIK3C2G* gene, rs12315677 has an 84% EAF in Hispanic (70-94% in other ancestries) and is only significantly associated with FG in this ancestry ($b = 0.0387$ mmol/l, $SE = 0.0075$ mmol/l, $P = 4.0 \times 10^{-8}$ vs $b = -0.0128$ - 0.010 mmol/l, $SE = 0.003$ - 0.018 mmol/l, $P = 0.14$ - 0.76 in all other ancestries, **Supplementary note**). In mice, deletion of *Pik3c2g* leads to a phenotype characterized by reduced glycogen storage in the liver, hyperlipidemia, adiposity, and insulin resistance with increasing age, or after a high fat diet²⁹. Instances of similar EAFs but differing effect sizes between populations, could be due to genotype-by-environment or other epistatic effects. Alternatively, lower imputation accuracy in smaller sample sizes could deflate effect sizes, although imputation quality for these variants was good (average $r^2 = 0.81$). Finally, the variants detected here may be in LD with ancestry-specific causal variants not interrogated here that differ in frequency across ancestries. However, we could not find evidence of rarer alleles in the cognate populations from the 1000G project (**Supplementary Table 5**). The final three single-ancestry loci were identified in individuals of European ancestry (**Supplementary note**).

Next, by rescaling the standard errors of allelic effect sizes to artificially boost the sample size of the European meta-analysis to match that of trans-ancestry meta-analysis, we determined that 21 of the novel trans-ancestry loci would not have been discovered with an equivalent sample size comprised exclusively of European ancestry individuals (**Supplementary note**). Their discovery was due to the higher EAF and/or larger effect size in non-European ancestry populations. In particular, two loci (near *LINC00885* and *MIR4278*) contain East Asian and African American single-ancestry lead variants, respectively, suggesting that these specific ancestries may be driving the trans-ancestry discovery (**Supplementary Tables 2-3**). Combined with the three single-ancestry non-European loci described above, our results show that 24% (24/99) of novel loci were discovered due to the contribution of non-European ancestry participants, strengthening the argument for expanding genetic studies in diverse populations.

Allelic architecture of glycemic traits

Single-ancestry and trans-ancestry results combined increased the number of established loci for FG to 102 (182 signals, 53 novel loci), FI to 66 (95 signals, 49 novel loci), 2hGlu to 21 (28 signals, 11 novel loci), and HbA1c to 127 (218 signals, 62 novel loci) (**Supplementary Table 2**), with significant overlap across traits (**Extended Data Figure 3**). We also detected ($P < 0.05$ or $\log_{10}BF > 0$) the vast majority (~90%) of previously established glycemic signals, 70-88% of which attained genome-wide significance (**Supplementary Note, Supplementary Table 6**). Given that analyses for FG, FI, and 2hGlu were performed adjusted for BMI, we confirmed that collider bias did not influence >98% of signals discovered (**Supplementary note**)³¹. As expected, given the greater power due to increased sample sizes, new association signals tended to have smaller effect sizes and/or EAFs in European ancestry individuals compared to established signals (**Extended Data Figure 4**).

Characterization of lead variants across ancestries

To better understand the transferability of trans-ancestry lead variants across ancestries, we investigated the pairwise EAF correlation and the pairwise summarized heterogeneity of effect sizes between ancestries³² (**Methods, Supplementary Note**). Consistent with population history and evolution, these results demonstrated considerable EAF correlation ($\rho^2 > 0.70$) between European and Hispanic, European and South Asian, and Hispanic and South Asian populations, consistent across all four traits, and between African Americans and Ugandans for HbA1c (**Extended Data Figure 5**). Despite significant EAF correlations, some pairwise comparisons exhibited strong evidence for effect size heterogeneity between ancestries that was less consistent between traits (**Extended Data Figure 5**). However, sensitivity analyses demonstrated that, across all comparisons, the evidence for heterogeneity is driven by a small number of variants, with between 81.5% (for HbA1c) and 85.7% of trans-ancestry lead variants (for FG) showing no evidence for trans-ancestry heterogeneity ($P > 0.05$) (**Supplementary Note**).

Trait variance explained by associated loci

The trait variance explained by genome-wide significant loci was assessed using the single-ancestry variants only or a combination of single-ancestry and trans-ancestry variants (**Supplementary Table 7**) with betas extracted from the relevant single-ancestry meta-analysis results (**Methods**). The variance explained was assessed by linear regression in a subset of the contributing cohorts (**Methods, Supplementary Tables 8-11**). In general, the approach that explained the most variance was to begin with the trans-ancestry lead variants that had $P < 0.1$ in the relevant single-ancestry meta-analysis, then add in all single-ancestry variants that were not in LD with the trans-ancestry variants ($LD\ r^2 < 0.1$) (List C, **Supplementary Tables 8-11, Figure 2**). Using this approach, the mean variance in the trait distribution explained was between 0.7% (2hGlu in EUR) and 6% (HbA1c in AA). The European-based estimates explained more variance relative to previous estimates of 2.8% for FG and 1.7% for HbA1c³³ (**Supplementary Note**).

Transferability of EUR ancestry-derived polygenic scores

To investigate the transferability of polygenic scores across ancestries we used the PRS-CSauto software³⁴ to first build polygenic scores for each glycemic trait based on European ancestry data. However, the training set for 2hGlu was too small so this trait was excluded. To build the polygenic scores (PGS), for each trait we first removed five of the largest European cohorts from the European ancestry meta-analysis. These five cohorts were meta-analyzed and used as our European ancestry test dataset, for each trait. The remaining European ancestry cohorts were also meta-analyzed and used as the training dataset, from which we derived a PGS for each trait (**Methods**). We used PRS-CSauto to revise the effect size estimates for the variants in the score (obtained from the training European datasets) based on the LD of the test population. PRS-CSauto does not have LD reference panels for South Asian or Hispanic ancestry and as such we were unable to test the transferability of the PGS into those populations. The “gtx” package³⁵ (**Methods**) was used to obtain the R^2 for each test population (**Figure 3, Supplementary Table 12**). Consistent with other complex traits³⁶, the

European ancestry-derived PGS had greater predictive power into test data of European ancestry than other ancestry groups.

Fine-mapping

We fine-mapped, 231 trans-ancestry and six single-ancestry autosomal loci (**Supplementary Table 2, Supplementary note**). Using FINEMAP with ancestry-specific LD and an average LD matrix across ancestries, we conducted fine-mapping both within (161 loci with single-ancestry lead variants) and across ancestries (231 loci) for each trait (**Methods**). Because 59 of the 231 trans-ancestry loci were associated with more than one trait, we conducted trans-ancestry fine-mapping for a total of 305 locus-trait associations. Of these 305 locus-trait combinations, FINEMAP estimated the presence of a single causal variant at 186 loci (61%), while multiple distinct causal variants were implicated at 126 loci (39%), for a total of 464 causal variants (**Figure 4A**).

Credible sets for causal variants

At each locus, we next constructed credible sets (CS) for each causal variant that account for $\geq 99\%$ of the posterior probability of association (PPA). We identified 21 locus-trait associations (at 19 loci) for which the 99% CS included a single variant, and we highlight four examples (**Methods, Supplementary Note, Figure 4B, Supplementary Table 13**).

At *MTNR1B* and *SIX3* we identified, respectively, rs10830963 (PPA >0.999 , for both HbA1c and FG) and rs12712928 (PPA=0.997, for FG) as the likely causal variants. At both loci previous studies confirm these variants affect transcriptional activity^{37,38,39} (**Supplementary note**). At a locus near *PFKM* associated with HbA1c, trans-ancestry fine-mapping identified rs12819124 (PPA >0.999) as the likely causal variant. This variant has been previously associated with mean corpuscular hemoglobin⁴⁰, suggesting an effect on HbA1c via the red blood cell (RBC, **Supplementary note**). At *HBB*, we identified rs334 (PPA >0.999 ; Glu7Val) as the likely causal variant associated with HbA1c. rs334 is a causal variant of sickle cell anemia⁴¹, previously associated with urinary albumin-to-creatinine ratio in Caribbean Hispanic individuals⁴², severe malaria in a Tanzanian study population⁴³, hematocrit and mean corpuscular volume in Hispanic/Latino populations⁴⁴, and RBC distribution in Ugandan individuals⁴⁵, all pointing to a variant effect on HbA1c via non-glycemic pathways.

The remaining locus-trait associations with a single variant in the 99% CS (**Supplementary Table 13**) point to variants that could be prioritized for functional follow-up to elucidate impact on glycemic trait physiology.

At an additional 156 locus-trait associations trans-ancestry fine-mapping identified 99% CS with 50 or fewer variants (**Figure 4B, Supplementary Table 13**). Consistent with the potential for >1 causal variant in a locus, 74 locus-trait associations contained 88 variants with PPA >0.90 that are strong candidate causal variants (**Supplementary Table 14**). For example, 10 are coding variants including several missense such as the *HBB* Glu7Val mentioned above, *GCKR* Leu446Pro, *RREB1* Asp1771Asn, *G6PC2* Pro324Ser, *GLP1R* Ala316Thr, and *TMPRSS6* Val736Ala, each of which have been proposed or shown to affect gene function^{12,46-50}. We additionally identified *AMPD3* Val311Leu (PPA=0.989) and *TMC6* Trp125Arg (PPA >0.999) variants associated with HbA1c which were previously detected in an exome array analysis but had not been fine-mapped with certainty due to the absence of backbone GWAS data³⁰. Our fine-mapping now suggest these variants are likely causal and identify their cognate genes as effector transcripts.

Finally, we evaluated the resolution obtained in the trans-ancestry versus single-ancestry fine-mapping (**Methods, Supplementary Note**). We compared the number of variants in 99% CS across 98 locus-trait associations which, as suggested by FINEMAP, had a single causal variant in both trans-ancestry and single-ancestry analyses. Fine-mapping within and across ancestries was conducted

using the same set of variants. At 8 of 98 locus-trait associations single-ancestry fine-mapping identified a single variant in the CS. In addition, at 72 of the 98 locus-trait associations, the number of variants in the 99% CS was smaller in the trans-ancestry fine-mapping (**Figure 4C**), which likely reflects the larger sample size and differences in LD structure, EAFs, and effect sizes across diverse populations. To quantify the estimated improvement in fine-mapping resolution attributable to the multi-ancestry GWAS, we then compared 99% CS sizes from the trans-ancestry fine-mapping to single-ancestry-specific data emulating the same total sample size by rescaling the standard errors (**Methods**). Of the 72 locus-trait associations with estimated improved fine-mapping in trans-ancestry analysis, resolution at 38 (53%) was improved because of the larger sample size in the trans-ancestry fine-mapping analysis (**Figure 4C**), and this estimated improved resolution would likely have been obtained in a European-only fine-mapping effort with equivalent sample size. However, at 34 (47%) loci, the inclusion of samples from multiple diverse populations yielded the estimated improved resolution. On average, ancestry differences led to a reduction in the median number of variants in the 99% CS from 24 to 15 variants (37.5% median reduction; **Figure 4C**), demonstrating the value of conducting fine-mapping across ancestries.

HbA1c Signal Classification

HbA1c-associated variants can exert their effects on HbA1c levels through both glycemic and non-glycemic pathways^{7,51} and their correct classification can affect T2D diagnostic accuracy^{7,52}. Using prior association results for other glycemic, RBC, and iron traits, and a fuzzy clustering approach we classified variants into their most likely mode of action (**Methods, Supplementary note**). Of the 218 HbA1c-associated variants, 27 (12%) could not be characterized due to missing data and 23 (11%) could not be classified into a “known” class (**Supplementary note**). The remaining signals were classified as principally: a) glycemic (n=53; 24%), b) affecting iron levels/metabolism (n=12; 6%), or c) RBC traits (n=103; 47%). A genetic risk score (GRS) composed of all HbA1c-associated signals was strongly associated with T2D risk (OR=2.4, 95% CI 2.3-2.5, $P=2.7 \times 10^{-298}$). However, when using partitioned GRSs composed of these different classes of variants (**Methods**), we found the T2D association was mainly driven by variants influencing HbA1c through glycemic pathways (OR=2.6, 95% CI 2.5-2.8, $P=2.3 \times 10^{-250}$), with weaker evidence of association (despite the larger number of variants in the GRS) and a more modest risk (OR=1.4, 95% CI 1.2-1.7, $P=4.7 \times 10^{-4}$) imparted by signals in the mature RBC cluster that were not glycemic (i.e. where those specific variants had $P>0.05$ for FI, 2hGlu and FG) (**Extended Data Figure 6, Supplementary note**). This contrasts our previous finding where we found no significant association between a risk score of non-glycemic variants and T2D⁷. Our current results could be partly driven by T2D cases being diagnosed based on HbA1c levels that may be influenced by the non-glycemic signals, or by glycemic effects not captured by FI, 2hGlu or FG measures.

Biological signatures of glycemic trait associated loci

To better understand distinct and shared biological signatures underlying variant-trait associations, we conducted genomic feature enrichment, eQTL co-localization, and tissue and gene-set enrichment analyses across all four traits.

Epigenomic landscape of trait-associated variants

We explored the genomic context underlying glycemic trait loci by computing overlap enrichment for annotations such as coding, conserved regions, and super enhancers merged across multiple cell types⁵³⁻⁵⁵ using the GREGOR tool⁵⁶. We observed that FG, FI and HbA1c signals (**Supplementary Table 7**) were significantly ($P<8.4 \times 10^{-4}$, Bonferroni threshold for 59 annotations) enriched in evolutionarily conserved regions (**Fig 5A, Extended Data Figure 7, Supplementary Table 15**).

We then considered epigenomic landscapes defined in individual cell/tissue types. Previously, stretch enhancers (StrE, enhancer chromatin states $\geq 3\text{kb}$ in length) in pancreatic islets were shown to be highly cell-specific and strongly enriched with T2D risk signals⁵⁷. Considering StrEs across 31 cell-types³⁹, FG and 2hGlu signals showed the highest enrichment in islets (FG: fold-enrichment=4.70, $P=2.7 \times 10^{-24}$; 2hGlu: fold-enrichment=5.51, $P=3.6 \times 10^{-4}$ **Figure 5A, Supplementary Table 16**), highlighting the importance of islets for these traits. FI signals were enriched in skeletal muscle (fold-enrichment=3.17, $P=7.8 \times 10^{-6}$) and adipose StrEs (fold-enrichment=3.27, $P=1.8 \times 10^{-7}$) consistent with these tissues as targets of insulin action (**Figure 5A**). StrEs in individual cell types showed higher enrichment than super enhancers merged across cell types, highlighting the importance of cell-specific analyses (**Figure 5A**). HbA1c signals were enriched in StrEs of multiple cell types and tissues, but have the strongest enrichment in K562 blood-derived leukemia cells (fold-enrichment=3.24, $P=1.2 \times 10^{-7}$, **Figure 5A**). Among the “hard” glycemic and red blood cell (mature + reticulocyte) HbA1c signals, glycemic signals were enriched in islet StrEs (fold-enrichment=3.96, $P=3.7 \times 10^{-16}$) while red blood cell signals were enriched in K562 StrEs (fold-enrichment=7.5, $P=2.08 \times 10^{-14}$, **Figure 5B, Supplementary Table 17**). These analyses suggest that these glycemic trait-associated variants influence the function of tissue-specific enhancers.

Independent analyses with fGWAS⁵⁸ and GARFIELD⁵⁹ yielded consistent results (**Extended Data Figures 8 and 9, Supplementary Tables 16 and 18**). Notably, FI signals at a lenient threshold of $P < 10^{-5}$ were enriched in liver StrEs using GARFIELD (odds ratio=1.92, $P=1.7 \times 10^{-4}$) (**Extended Data Figure 9A**). This suggests that liver regulatory annotations are relevant for FI GWAS signals, but that we lack power to detect significant enrichment using the genome-wide significant loci and the current set of reference annotations.

We next explored the 27 loci driving the FI enrichment in adipose and skeletal muscle, 11 of which overlapped StrEs in both tissues (**Figure 5C**). At the *COL4A2* locus, variants within an intronic region overlap StrEs in adipose tissue, skeletal muscle, and a human skeletal muscle myoblast (HSMM) cell line that are not shared across other cell/tissue types. Among these, rs9555695 (in the 99% CS) also overlaps accessible chromatin regions in adipose (**Figure 5D**). At a narrow signal with no proxy variants ($\text{LD } r^2 > 0.7$ in Europeans), the lead trans-ancestry variant rs62271373 (PPA = 0.94) located in an intergenic region ~25kb from the *LINC01214* gene overlaps StrEs specific to adipose and HSMM and an active enhancer chromatin state in skeletal muscle (**Figure 5E**). Collectively, the tissue-specific epigenomic signatures at GWAS signals provide an opportunity to nominate tissues where these variants are likely to be active. This map may help future efforts to deconvolute GWAS signals into tissue-specific disease pathology.

Co-localization of GWAS and eQTLs

Among the 99 novel glycemic trait loci, we identified co-localized eQTLs at 34 loci in blood, pancreatic islets, subcutaneous or visceral adipose, skeletal muscle, or liver, providing suggestive evidence of causal genes (**Supplementary Table 19**). The co-localized eQTLs include several genes previously reported at glycemic trait loci: *ADCY5*, *CAMK1D*, *IRS1*, *JAZF1*, and *KLF14*⁶⁰⁻⁶². For some additional loci, the co-localized genes have prior evidence for a role in glycemic regulation. For example, the lead trans-ancestry variant and likely causal variant, rs1799815 (PPA=0.993), associated with FI is the strongest variant associated with expression of *INSR*, encoding the insulin receptor, in subcutaneous adipose from METSIM ($P=2 \times 10^{-9}$) and GTEx ($P=5 \times 10^{-6}$). The A allele at rs1799815 is associated with higher FI and lower expression of *INSR*, consistent with the relationship between insulin resistance and reduced INSR function⁶³. In a second example, rs841572, the trans-ancestry lead variant associated with FG, has the highest PPA (PPA=0.535) among the 20 variants in the 99% CS and is in strong LD ($r^2=0.87$) with the lead eQTL variant (rs841576, also in the 99% CS) associated with *SLC2A1* expression in blood (eQTLGen $P=1 \times 10^{-8}$). *SLC2A1*, also known as *GLUT1*,

encodes the major glucose transporter in brain, placenta, and erythrocytes, and is responsible for glucose entry into the brain⁶⁴. rs841572-A is associated with lower FG and lower *SLC2A1* expression. While rare missense variants in *SLC2A1* are an established cause of seizures and epilepsy⁶⁵, our data suggest that *SLC2A1* variants also affect plasma glucose levels within a population. These co-localized signals provide possible regulatory mechanisms for variant effects on genes to influence glycemic traits.

The co-localized eQTLs also provide new insights into the mechanisms at glycemic trait loci. For example, rs9884482 (in the 99% CS) is associated with FI and *TET2* expression in subcutaneous adipose ($P=2 \times 10^{-20}$); rs9884482 is in high LD ($r^2=0.96$ in Europeans) with the lead *TET2* eQTL variant (rs974801). *TET2* encodes a DNA-demethylase that can affect transcriptional repression⁶⁶. Adipose Tet2 expression is reduced in diet-induced insulin resistance in mice⁶⁷, and knockdown of Tet2 blocked adipogenesis^{67,68}. Consistently, in human adipose tissue, rs9884482-C was associated with lower *TET2* expression and higher FI. In a second example, rs617948 is associated with HbA1c (in the 99% CS) and is the lead variant associated with *C2CD2L* expression in blood (eQTLGen $P=3 \times 10^{-96}$). *C2CD2L*, also known as *TMEM24*, regulates pulsatile insulin secretion and facilitates release of insulin pool reserves^{69,70}. rs617948-G was associated with higher HbA1c and lower *C2CD2L*, providing evidence for a role of this insulin secretion protein in glucose homeostasis. Our HbA1c “soft” clustering assigned this signal to both the “unknown” (0.51 probability) and “reticulocyte” (0.42 probability) clusters. rs617948 is strongly associated with HbA1c ($P<6.8 \times 10^{-8}$), but not with FG, FI or 2hGlu ($P>0.05$, **Supplementary Table 20, Supplementary Note**). This suggests an effect of this variant on reticulocyte biology, and on insulin secretion, potentially influencing HbA1c levels through different tissues, and providing a plausible explanation for the classification as “unknown”.

Tissue Expression

Consistent with effector transcript expression analysis using GTEx data³⁰, we found significant differences in tissue expression across the glycemic trait signals. FG signals were enriched for genes expressed in the pancreas ($FDR<0.05$), while there were an insufficient number of significant associations in 2hGlu to identify enrichment for any tissue or cell type at $FDR<0.2$ threshold. FI signals were enriched for connective tissue and cells (which includes adipose tissue), endocrine glands, blood cells, and muscles ($FDR<0.2$) and HbA1c signals were significantly enriched for genes expressed in the pancreas, hemic, and immune system ($FDR<0.05$) (**Figure 6, Supplementary Table 21**). Consistent with previous analysis³⁰, FI-enrichment for connective tissue was driven by adipose tissue (subcutaneous and visceral), while the newly described enrichment with endocrine glands was driven by the adrenal glands and cortex (**Supplementary Table 21**). Beyond enrichment for genes expressed in glycemic-related tissues, HbA1c signals were enriched with genes expressed in blood, consistent with the role of RBC in this trait and our previous results³⁰.

The association between FI signals and genes expressed in adrenal glands is notable, suggesting a possible direct role for these genes in insulin resistance. These genes might influence cortisol levels, which could contribute to insulin resistance and FI levels through impaired insulin receptor signaling in peripheral tissues, as well as influencing body fat distribution, stimulate lipolysis, and other indirect mechanisms^{71,72}.

Gene-set Analyses

Next, we performed gene-set analysis using DEPICT (**Methods**). In keeping with previous results³⁰, we found distinct gene-sets enriched ($FDR<0.05$) for each glycemic trait except 2hGlu, which had insufficient associations to have power in this analysis. FG-associated variants highlighted gene-sets involved in metabolism and gene-sets involved in general cellular function such as “cytoplasmic vesicle membrane” and “circadian clock” (**Figure 7A**). In contrast, in addition to metabolism-related

gene-sets, FI-associated variants highlighted pathways related to growth, cancer and reproduction (**Figure 7B**). This is consistent with the role of insulin as a mitogenic hormone, and with epidemiological links between insulin and certain types of cancer⁷³ and reproductive disorders such as polycystic ovary syndrome⁷⁴. HbA1c-associated variants highlighted many gene-sets (**Figure 7C**), including those linked to metabolism and hematopoiesis, again recapitulating our postulated effects of variants on glucose and RBC biology. Additional pathways from HbA1c-associated variants also highlighted previous “CREBP PPI” and lipid biology related to T2D⁷⁵ and HbA1c⁷⁶, respectively, and potential new biology through which variants may influence HbA1c.

Discussion

Here we describe a large glycemic trait meta-analysis of GWAS for which 30% of the population was composed of East Asian, Hispanic, African-American, South Asian and sub-Saharan African participants. This effort identified 242 loci (235 trans-ancestry and seven single-ancestry), which jointly explain between 0.7% (2hGlu in European ancestry individuals) and 6% (HbA1c in African American ancestry individuals) of the variance in glycemic traits in any given ancestry. While 114/242 loci are associated with T2D ($P < 10^{-4}$; 83 loci with $P < 5 \times 10^{-8}$, **Supplementary Table 4**), absence of strong evidence of association at the remaining loci ($P \geq 10^{-4}$) suggests that for alleles more frequent than 5% we can exclude T2D ORs ≥ 1.07 with 80% power ($\alpha = 5 \times 10^{-8}$; and ORs ≥ 1.05 for $\alpha = 10^{-4}$) given a current study of 228,499 T2D cases and 1,178,783 controls²⁷. We identified 486 signals associated with glycemic traits, of which eight have MAF $< 1\%$, and 45 have $1\% \leq \text{MAF} < 5\%$ in all ancestries, highlighting that 89% of signals identified are common in at least one ancestry studied.

A key aim of our study was to evaluate the added advantage of including population diversity in genetic discovery and fine-mapping efforts. Beyond the larger sample size included in the trans-ancestry meta-analysis, we were able to estimate the contribution of non-European ancestry data in locus discovery and fine-mapping resolution. We found that 24 of the 99 newly discovered loci owe their discovery to the inclusion of East Asian, Hispanic, African-American, South Asian and sub-Saharan African participant data, due to differences in EAF and effect sizes across ancestries.

Comparison of 295 trans-ancestry lead variants (315 locus-trait associations) across ancestries demonstrated that between 81.5% (HbA1c) and 85.7% (FG) of the trans-ancestry lead variants had no evidence of trans-ancestry heterogeneity in allelic effects ($P > 0.05$).

Given sample size and power limitations, genome-wide significant trait-associated variants in a single-ancestry explain only a modest proportion of trait variance in that ancestry (**Figure 2**). We demonstrate that trans-ancestry lead variants explain more trait variance than the ancestry-specific variants (**Figure 2**). This shows that even though some trans-ancestry lead variants are not genome-wide significant in all ancestries, they contribute to the genetic architecture of the trait in most ancestries.

We evaluated for the first time the transferability of European ancestry-derived glycemic trait PGS into other ancestries. Consistent with other traits^{36,77,78}, we confirm that European ancestry-derived PGS perform much worse when the test dataset is from a different ancestry. Each trait-specific PGS improves trait variance explained by between 3.5-fold (HbA1c) and 6-fold (FG) in the European dataset (**Figure 3, Supplementary Table 12**) compared to a score built only from trans-ancestry lead variants and European index variants (**Figure 2, Supplementary tables 9-12**).

Despite development of approaches to derive polygenic risk scores⁷⁹, we note the difficulty in using summary level data to build a PGS in one ancestry and then apply it in test datasets of different ancestry. While PRS-CSauto³⁴ is able to use summary level data, revision of the effect size estimates

to account for LD required reference panels that matched the ancestry of the test dataset. However, the current software lacks appropriate reference panels for many ancestries, precluding its broad application. **Future developments of trans-ancestry PGS are required for improved cross-ancestry performance.**

We show that fine-mapping resolution is improved in trans-ancestry, compared to single-ancestry fine-mapping efforts. In ~50% of our loci, we showed that the improvement was due to differences in EAF, effect size, or LD structure between ancestries, and not just due to the overall increased sample size available for trans-ancestry fine-mapping. By performing trans-ancestry fine-mapping, and co-localizing GWAS signals with eQTL signals and coding variants, we identified new candidate causal genes. Altogether, these results motivate continued expansion of genetic and genomic efforts in diverse populations to improve understanding of these traits in groups disproportionately affected by T2D.

Given data on four different glycemic traits and their utility to diagnose and monitor T2D and metabolic health, we also sought to characterize biological features underlying these traits. We show that despite significant sharing of loci across the four traits, each trait is also characterized by unique features based on StrE, gene expression and gene-set signatures. Combining genetic data from these traits with T2D data will further elucidate pathways driving normal physiology and pathophysiology, and help further develop useful predictive scores for disease classification and management^{4,5}.

References

- 1 in *Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation* (World Health Organization Copyright © World Health Organization 2011., 2011).
- 2 Goodarzi, M. O. *et al.* Fasting insulin reflects heterogeneous physiological processes: role of insulin clearance. *American journal of physiology. Endocrinology and metabolism* **301**, E402-408, doi:10.1152/ajpendo.00013.2011 (2011).
- 3 Dimas, A. S. *et al.* Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity. *Diabetes* **63**, 2158-2171, doi:10.2337/db13-0949 (2014).
- 4 Udler, M. S. *et al.* Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis. *PLoS medicine* **15**, e1002654, doi:10.1371/journal.pmed.1002654 (2018).
- 5 Udler, M. S., McCarthy, M. I., Florez, J. C. & Mahajan, A. Genetic Risk Scores for Diabetes Diagnosis and Precision Medicine. *Endocrine reviews* **40**, 1500-1520, doi:10.1210/er.2019-00088 (2019).
- 6 Sarwar, N. *et al.* Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet* **375**, 2215-2222, doi:10.1016/s0140-6736(10)60484-9 (2010).
- 7 Wheeler, E. *et al.* Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis. *PLoS medicine* **14**, e1002383, doi:10.1371/journal.pmed.1002383 (2017).

925 8 Dupuis, J. *et al.* New genetic loci implicated in fasting glucose homeostasis and their
926 impact on type 2 diabetes risk. *Nature genetics* **42**, 105-116, doi:10.1038/ng.520
927 (2010).

928 9 Manning, A. K. *et al.* A genome-wide approach accounting for body mass index
929 identifies genetic variants influencing fasting glycemic traits and insulin resistance.
930 *Nature genetics* **44**, 659-669, doi:10.1038/ng.2274 (2012).

931 10 Walford, G. A. *et al.* Genome-Wide Association Study of the Modified Stumvoll
932 Insulin Sensitivity Index Identifies BCL2 and FAM19A2 as Novel Insulin Sensitivity
933 Loci. *Diabetes* **65**, 3200-3211, doi:10.2337/db16-0199 (2016).

934 11 Horikoshi, M. *et al.* Discovery and Fine-Mapping of Glycaemic and Obesity-Related
935 Trait Loci Using High-Density Imputation. *PLoS genetics* **11**, e1005230,
936 doi:10.1371/journal.pgen.1005230 (2015).

937 12 Mahajan, A. *et al.* Identification and functional characterization of G6PC2 coding
938 variants influencing glycemic traits define an effector transcript at the G6PC2-
939 ABCB11 locus. *PLoS genetics* **11**, e1004876, doi:10.1371/journal.pgen.1004876
940 (2015).

941 13 Hwang, J. Y. *et al.* Genome-wide association meta-analysis identifies novel variants
942 associated with fasting plasma glucose in East Asians. *Diabetes* **64**, 291-298,
943 doi:10.2337/db14-0563 (2015).

944 14 Chen, P. *et al.* Multiple nonglycemic genomic loci are newly associated with blood
945 level of glycated hemoglobin in East Asians. *Diabetes* **63**, 2551-2562,
946 doi:10.2337/db13-1815 (2014).

947 15 Scott, R. A. *et al.* Large-scale association analyses identify new loci influencing
948 glycemic traits and provide insight into the underlying biological pathways. *Nature*
949 *genetics* **44**, 991-1005, doi:10.1038/ng.2385 (2012).

950 16 Spanakis, E. K. & Golden, S. H. Race/ethnic difference in diabetes and diabetic
951 complications. *Current diabetes reports* **13**, 814-823, doi:10.1007/s11892-013-0421-
952 9 (2013).

953 17 Tillin, T. *et al.* Insulin resistance and truncal obesity as important determinants of the
954 greater incidence of diabetes in Indian Asians and African Caribbeans compared with
955 Europeans: the Southall And Brent REvisited (SABRE) cohort. *Diabetes care* **36**, 383-
956 393, doi:10.2337/dc12-0544 (2013).

957 18 Whincup, P. H. *et al.* Early emergence of ethnic differences in type 2 diabetes
958 precursors in the UK: the Child Heart and Health Study in England (CHASE Study).
959 *PLoS medicine* **7**, e1000263, doi:10.1371/journal.pmed.1000263 (2010).

960 19 Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**, 68-74,
961 doi:10.1038/nature15393 (2015).

962 20 Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of
963 genomewide association scans. *Bioinformatics (Oxford, England)* **26**, 2190-2191,
964 doi:10.1093/bioinformatics/btq340 (2010).

965 21 Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide
966 complex trait analysis. *American journal of human genetics* **88**, 76-82,
967 doi:10.1016/j.ajhg.2010.11.011 (2011).

968 22 Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics
969 identifies additional variants influencing complex traits. *Nature genetics* **44**, 369-375,
970 s361-363, doi:10.1038/ng.2213 (2012).

971 23 Genome-wide association study of 14,000 cases of seven common diseases and
972 3,000 shared controls. *Nature* **447**, 661-678, doi:10.1038/nature05911 (2007).

973 24 Mahajan, A. *et al.* Trans-ancestry genetic study of type 2 diabetes highlights the
974 power of diverse populations for discovery and translation. *medRxiv*,
975 2020.2009.2022.20198937, doi:10.1101/2020.09.22.20198937 (2020).

976 25 Mahajan, A. *et al.* Fine-mapping type 2 diabetes loci to single-variant resolution
977 using high-density imputation and islet-specific epigenome maps. *Nature genetics*
978 **50**, 1505-1513, doi:10.1038/s41588-018-0241-6 (2018).

979 26 Spracklen, C. N. *et al.* Identification of type 2 diabetes loci in 433,540 East Asian
980 individuals. *Nature* **582**, 240-245, doi:10.1038/s41586-020-2263-3 (2020).

981 27 Vujkovic, M. *et al.* Discovery of 318 new risk loci for type 2 diabetes and related
982 vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis.
983 *Nature genetics* **52**, 680-691, doi:10.1038/s41588-020-0637-y (2020).

984 28 Luo, Y. *et al.* Transcription factor Ets1 regulates expression of thioredoxin-interacting
985 protein and inhibits insulin secretion in pancreatic beta-cells. *PLoS one* **9**, e99049,
986 doi:10.1371/journal.pone.0099049 (2014).

987 29 Braccini, L. *et al.* PI3K-C2gamma is a Rab5 effector selectively controlling endosomal
988 Akt2 activation downstream of insulin signalling. *Nature communications* **6**, 7400,
989 doi:10.1038/ncomms8400 (2015).

990 30 Ng, N. H. J. *et al.* Tissue-Specific Alteration of Metabolic Pathways Influences
991 Glycemic Regulation. *bioRxiv*, 790618, doi:10.1101/790618 (2019).

992 31 Aschard, H., Vilhjalmsen, B. J., Joshi, A. D., Price, A. L. & Kraft, P. Adjusting for
993 heritable covariates can bias effect estimates in genome-wide association studies.
994 *American journal of human genetics* **96**, 329-339, doi:10.1016/j.ajhg.2014.12.021
995 (2015).

996 32 Lee, J. J. *et al.* Gene discovery and polygenic prediction from a genome-wide
997 association study of educational attainment in 1.1 million individuals. *Nature*
998 *genetics* **50**, 1112-1121, doi:10.1038/s41588-018-0147-3 (2018).

999 33 Nolte, I. M. *et al.* Missing heritability: is the gap closing? An analysis of 32 complex
1000 traits in the Lifelines Cohort Study. *European journal of human genetics : EJHG* **25**,
1001 877-885, doi:10.1038/ejhg.2017.50 (2017).

1002 34 Ge, T., Chen, C. Y., Ni, Y., Feng, Y. A. & Smoller, J. W. Polygenic prediction via
1003 Bayesian regression and continuous shrinkage priors. *Nature communications* **10**,
1004 1776, doi:10.1038/s41467-019-09718-5 (2019).

1005 35 Dastani, Z. *et al.* Novel loci for adiponectin levels and their influence on type 2
1006 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals.
1007 *PLoS genetics* **8**, e1002607, doi:10.1371/journal.pgen.1002607 (2012).

1008 36 Martin, A. R. *et al.* Clinical use of current polygenic risk scores may exacerbate health
1009 disparities. *Nature genetics* **51**, 584-591, doi:10.1038/s41588-019-0379-x (2019).

1010 37 Gaulton, K. J. *et al.* Genetic fine mapping and genomic annotation defines causal
1011 mechanisms at type 2 diabetes susceptibility loci. *Nature genetics* **47**, 1415-1425,
1012 doi:10.1038/ng.3437 (2015).

1013 38 Spracklen, C. N. *et al.* Identification and functional analysis of glycemic trait loci in
1014 the China Health and Nutrition Survey. *PLoS genetics* **14**, e1007275,
1015 doi:10.1371/journal.pgen.1007275 (2018).

1016 39 Varshney, A. *et al.* Genetic regulatory signatures underlying islet gene expression
1017 and type 2 diabetes. *Proceedings of the National Academy of Sciences of the United*
1018 *States of America* **114**, 2301-2306, doi:10.1073/pnas.1621192114 (2017).

1019 40 Kichaev, G. *et al.* Leveraging Polygenic Functional Enrichment to Improve GWAS
1020 Power. *American journal of human genetics* **104**, 65-75,
1021 doi:10.1016/j.ajhg.2018.11.008 (2019).

1022 41 Shriner, D. & Rotimi, C. N. Whole-Genome-Sequence-Based Haplotypes Reveal Single
1023 Origin of the Sickle Allele during the Holocene Wet Phase. *American journal of*
1024 *human genetics* **102**, 547-556, doi:10.1016/j.ajhg.2018.02.003 (2018).

1025 42 Kramer, H. J. *et al.* African Ancestry-Specific Alleles and Kidney Disease Risk in
1026 Hispanics/Latinos. *Journal of the American Society of Nephrology : JASN* **28**, 915-922,
1027 doi:10.1681/asn.2016030357 (2017).

1028 43 Ravenhall, M. *et al.* Novel genetic polymorphisms associated with severe malaria and
1029 under selective pressure in North-eastern Tanzania. *PLoS genetics* **14**, e1007172,
1030 doi:10.1371/journal.pgen.1007172 (2018).

1031 44 Hodonsky, C. J. *et al.* Genome-wide association study of red blood cell traits in
1032 Hispanics/Latinos: The Hispanic Community Health Study/Study of Latinos. *PLoS*
1033 *genetics* **13**, e1006760, doi:10.1371/journal.pgen.1006760 (2017).

1034 45 Gurdasani, D. *et al.* Uganda Genome Resource Enables Insights into Population
1035 History and Genomic Discovery in Africa. *Cell* **179**, 984-1002.e1036,
1036 doi:10.1016/j.cell.2019.10.004 (2019).

1037 46 Rees, M. G. *et al.* Cellular characterisation of the GCKR P446L variant associated with
1038 type 2 diabetes risk. *Diabetologia* **55**, 114-122, doi:10.1007/s00125-011-2348-5
1039 (2012).

1040 47 Bonomo, J. A. *et al.* The ras responsive transcription factor RREB1 is a novel
1041 candidate gene for type 2 diabetes associated end-stage kidney disease. *Human*
1042 *molecular genetics* **23**, 6441-6447, doi:10.1093/hmg/ddu362 (2014).

1043 48 Wessel, J. *et al.* Low-frequency and rare exome chip variants associate with fasting
1044 glucose and type 2 diabetes susceptibility. *Nature communications* **6**, 5897,
1045 doi:10.1038/ncomms6897 (2015).

1046 49 Scott, R. A. *et al.* A genomic approach to therapeutic target validation identifies a
1047 glucose-lowering GLP1R variant protective for coronary heart disease. *Science*
1048 *translational medicine* **8**, 341ra376, doi:10.1126/scitranslmed.aad3744 (2016).

1049 50 Nai, A. *et al.* TMPRSS6 rs855791 modulates hepcidin transcription in vitro and serum
1050 hepcidin levels in normal individuals. *Blood* **118**, 4459-4462, doi:10.1182/blood-
1051 2011-06-364034 (2011).

1052 51 Soranzo, N. *et al.* Common variants at 10 genomic loci influence hemoglobin A(1)(C)
1053 levels via glycemic and nonglycemic pathways. *Diabetes* **59**, 3229-3239,
1054 doi:10.2337/db10-0502 (2010).

1055 52 Sarnowski, C. *et al.* Impact of Rare and Common Genetic Variants on Diabetes
1056 Diagnosis by Hemoglobin A1c in Multi-Ancestry Cohorts: The Trans-Omics for
1057 Precision Medicine Program. *American journal of human genetics* **105**, 706-718,
1058 doi:10.1016/j.ajhg.2019.08.010 (2019).

1059 53 Kundaje, A. *et al.* Integrative analysis of 111 reference human epigenomes. *Nature*
1060 **518**, 317-330, doi:10.1038/nature14248 (2015).

1061 54 Nagel, M. *et al.* Meta-analysis of genome-wide association studies for neuroticism in
1062 449,484 individuals identifies novel genetic loci and pathways. *Nature genetics* **50**,
1063 920-927, doi:10.1038/s41588-018-0151-7 (2018).

1064 55 Savage, J. E. *et al.* Genome-wide association meta-analysis in 269,867 individuals
1065 identifies new genetic and functional links to intelligence. *Nature genetics* **50**, 912-
1066 919, doi:10.1038/s41588-018-0152-6 (2018).

1067 56 Schmidt, E. M. *et al.* GREGOR: evaluating global enrichment of trait-associated
1068 variants in epigenomic features using a systematic, data-driven approach.
1069 *Bioinformatics (Oxford, England)* **31**, 2601-2606, doi:10.1093/bioinformatics/btv201
1070 (2015).

1071 57 Parker, S. C. *et al.* Chromatin stretch enhancer states drive cell-specific gene
1072 regulation and harbor human disease risk variants. *Proceedings of the National*
1073 *Academy of Sciences of the United States of America* **110**, 17921-17926,
1074 doi:10.1073/pnas.1317023110 (2013).

1075 58 Pickrell, J. K. Joint analysis of functional genomic data and genome-wide association
1076 studies of 18 human traits. *American journal of human genetics* **94**, 559-573,
1077 doi:10.1016/j.ajhg.2014.03.004 (2014).

1078 59 Iotchkova, V. *et al.* GARFIELD classifies disease-relevant genomic features through
1079 integration of functional annotations with association signals. *Nature genetics* **51**,
1080 343-353, doi:10.1038/s41588-018-0322-6 (2019).

1081 60 van de Bunt, M. *et al.* Transcript Expression Data from Human Islets Links Regulatory
1082 Signals from Genome-Wide Association Studies for Type 2 Diabetes and Glycemic
1083 Traits to Their Downstream Effectors. *PLoS genetics* **11**, e1005694,
1084 doi:10.1371/journal.pgen.1005694 (2015).

1085 61 Civelek, M. *et al.* Genetic Regulation of Adipose Gene Expression and Cardio-
1086 Metabolic Traits. *American journal of human genetics* **100**, 428-443,
1087 doi:10.1016/j.ajhg.2017.01.027 (2017).

1088 62 Scott, L. J. *et al.* The genetic regulatory signature of type 2 diabetes in human
1089 skeletal muscle. *Nature communications* **7**, 11764, doi:10.1038/ncomms11764
1090 (2016).

1091 63 Ben Harouch, S., Klar, A. & Falik Zaccai, T. C. in *GeneReviews((R))* (eds M. P. Adam *et*
1092 *al.*) (University of Washington, Seattle
1093 University of Washington, Seattle. GeneReviews is a registered trademark of the University
1094 of Washington, Seattle. All rights reserved., 1993).

1095 64 Agus, D. B. *et al.* Vitamin C crosses the blood-brain barrier in the oxidized form
1096 through the glucose transporters. *The Journal of clinical investigation* **100**, 2842-
1097 2848, doi:10.1172/jci119832 (1997).

1098 65 Wolking, S. *et al.* Focal epilepsy in glucose transporter type 1 (Glut1) defects: case
1099 reports and a review of literature. *Journal of neurology* **261**, 1881-1886,
1100 doi:10.1007/s00415-014-7433-5 (2014).

1101 66 Guallar, D. *et al.* RNA-dependent chromatin targeting of TET2 for endogenous
1102 retrovirus control in pluripotent stem cells. *Nature genetics* **50**, 443-451,
1103 doi:10.1038/s41588-018-0060-9 (2018).

1104 67 Bian, F. *et al.* TET2 facilitates PPARGamma agonist-mediated gene regulation and
1105 insulin sensitization in adipocytes. *Metabolism: clinical and experimental* **89**, 39-47,
1106 doi:10.1016/j.metabol.2018.08.006 (2018).

1107 68 Yoo, Y. *et al.* TET-mediated hydroxymethylcytosine at the Ppargamma locus is
1108 required for initiation of adipogenic differentiation. *International journal of obesity*
1109 (2005) **41**, 652-659, doi:10.1038/ijo.2017.8 (2017).

1110 69 Lees, J. A. *et al.* Lipid transport by TMEM24 at ER-plasma membrane contacts
1111 regulates pulsatile insulin secretion. *Science (New York, N.Y.)* **355**,
1112 doi:10.1126/science.aah6171 (2017).

1113 70 Pottekat, A. *et al.* Insulin biosynthetic interaction network component, TMEM24,
1114 facilitates insulin reserve pool release. *Cell reports* **4**, 921-930,
1115 doi:10.1016/j.celrep.2013.07.050 (2013).

1116 71 Androulakis, I *et al.* Patients with apparently nonfunctioning adrenal incidentalomas
1117 may be at increased cardiovascular risk due to excessive cortisol secretion. *The*
1118 *Journal of clinical endocrinology and metabolism* **99**, 2754-2762,
1119 doi:10.1210/jc.2013-4064 (2014).

1120 72 Altieri, B. *et al.* Adrenocortical tumors and insulin resistance: What is the first step?
1121 *International journal of cancer* **138**, 2785-2794, doi:10.1002/ijc.29950 (2016).

1122 73 Johansson, M. *et al.* The influence of obesity-related factors in the etiology of renal
1123 cell carcinoma-A mendelian randomization study. *PLoS medicine* **16**, e1002724,
1124 doi:10.1371/journal.pmed.1002724 (2019).

1125 74 Diamanti-Kandarakis, E. & Dunaif, A. Insulin resistance and the polycystic ovary
1126 syndrome revisited: an update on mechanisms and implications. *Endocrine reviews*
1127 **33**, 981-1030, doi:10.1210/er.2011-1034 (2012).

1128 75 Morris, A. P. *et al.* Large-scale association analysis provides insights into the genetic
1129 architecture and pathophysiology of type 2 diabetes. *Nature genetics* **44**, 981-990,
1130 doi:10.1038/ng.2383 (2012).

1131 76 Leong, A. *et al.* Mendelian Randomization Analysis of Hemoglobin A(1c) as a Risk
1132 Factor for Coronary Artery Disease. *Diabetes care* **42**, 1202-1208, doi:10.2337/dc18-
1133 1712 (2019).

1134 77 Duncan, L. *et al.* Analysis of polygenic risk score usage and performance in diverse
1135 human populations. *Nature communications* **10**, 3328, doi:10.1038/s41467-019-
1136 11112-0 (2019).

1137 78 Mostafavi, H. *et al.* Variable prediction accuracy of polygenic scores within an
1138 ancestry group. *eLife* **9**, doi:10.7554/eLife.48376 (2020).

1139 79 Choi, S. W., Mak, T. S. & O'Reilly, P. F. Tutorial: a guide to performing polygenic risk
1140 score analyses. *Nature protocols* **15**, 2759-2772, doi:10.1038/s41596-020-0353-1
1141 (2020).

1142 80 D'Orazio, P. *et al.* Approved IFCC recommendation on reporting results for blood
1143 glucose (abbreviated). *Clinical chemistry* **51**, 1573-1576,
1144 doi:10.1373/clinchem.2005.051979 (2005).

1145 81 Voight, B. F. *et al.* The metabochip, a custom genotyping array for genetic studies of
1146 metabolic, cardiovascular, and anthropometric traits. *PLoS genetics* **8**, e1002793,
1147 doi:10.1371/journal.pgen.1002793 (2012).

1148 82 Abecasis, G. R. *et al.* An integrated map of genetic variation from 1,092 human
1149 genomes. *Nature* **491**, 56-65, doi:10.1038/nature11632 (2012).

1150 83 Li, Y., Willer, C. J., Ding, J., Scheet, P. & Abecasis, G. R. MaCH: using sequence and
1151 genotype data to estimate haplotypes and unobserved genotypes. *Genetic*
1152 *epidemiology* **34**, 816-834, doi:10.1002/gepi.20533 (2010).

1153 84 Pei, Y. F., Zhang, L., Li, J. & Deng, H. W. Analyses and comparison of imputation-
1154 based association methods. *PloS one* **5**, e10827, doi:10.1371/journal.pone.0010827
1155 (2010).

1156 85 Winkler, T. W. *et al.* Quality control and conduct of genome-wide association meta-
1157 analyses. *Nature protocols* **9**, 1192-1212, doi:10.1038/nprot.2014.071 (2014).

1158 86 Devlin, B. & Roeder, K. Genomic control for association studies. *Biometrics* **55**, 997-
1159 1004 (1999).

1160 87 Morris, A. P. Transethnic meta-analysis of genomewide association studies. *Genetic*
1161 *epidemiology* **35**, 809-822, doi:10.1002/gepi.20630 (2011).

1162 88 Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from
1163 polygenicity in genome-wide association studies. *Nature genetics* **47**, 291-295,
1164 doi:10.1038/ng.3211 (2015).

1165 89 Dastani, Z. *et al.* Novel loci for adiponectin levels and their influence on type 2
1166 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals.
1167 *PLoS genetics* **8**, e1002607, doi:10.1371/journal.pgen.1002607 (2012).

1168 90 Benner, C. *et al.* FINEMAP: efficient variable selection using summary data from
1169 genome-wide association studies. *Bioinformatics (Oxford, England)* **32**, 1493-1501,
1170 doi:10.1093/bioinformatics/btw018 (2016).

1171 91 Astle, W. J. *et al.* The Allelic Landscape of Human Blood Cell Trait Variation and Links
1172 to Common Complex Disease. *Cell* **167**, 1415-1429.e1419,
1173 doi:10.1016/j.cell.2016.10.042 (2016).

1174 92 Canela-Xandri, O., Rawlik, K. & Tenesa, A. An atlas of genetic associations in UK
1175 Biobank. *Nature genetics* **50**, 1593-1599, doi:10.1038/s41588-018-0248-z (2018).

1176 93 Benyamin, B. *et al.* Novel loci affecting iron homeostasis and their effects in
1177 individuals at risk for hemochromatosis. *Nature communications* **5**, 4926,
1178 doi:10.1038/ncomms5926 (2014).

1179 94 Binesh, N. & Rezghi, M. Fuzzy clustering in community detection based on
1180 nonnegative matrix factorization with two novel evaluation criteria. *Applied Soft*
1181 *Computing* **69**, 689-703 (2018).

1182 95 Scott, R. A. *et al.* An Expanded Genome-Wide Association Study of Type 2 Diabetes in
1183 Europeans. *Diabetes* **66**, 2888-2902, doi:10.2337/db16-1253 (2017).

1184 96 Ernst, J. *et al.* Mapping and analysis of chromatin state dynamics in nine human cell
1185 types. *Nature* **473**, 43-49, doi:10.1038/nature09906 (2011).

1186 97 Mikkelsen, T. S. *et al.* Comparative epigenomic analysis of murine and human
1187 adipogenesis. *Cell* **143**, 156-169, doi:10.1016/j.cell.2010.09.006 (2010).

1188 98 Ernst, J. & Kellis, M. ChromHMM: automating chromatin-state discovery and
1189 characterization. *Nature methods* **9**, 215-216, doi:10.1038/nmeth.1906 (2012).

1190 99 Battle, A., Brown, C. D., Engelhardt, B. E. & Montgomery, S. B. Genetic effects on
1191 gene expression across human tissues. *Nature* **550**, 204-213,
1192 doi:10.1038/nature24277 (2017).

1193 100 Zhernakova, D. V. *et al.* Identification of context-dependent expression quantitative
1194 trait loci in whole blood. *Nature genetics* **49**, 139-145, doi:10.1038/ng.3737 (2017).

1195 101 Westra, H. J. *et al.* Systematic identification of trans eQTLs as putative drivers of
1196 known disease associations. *Nature genetics* **45**, 1238-1243, doi:10.1038/ng.2756
1197 (2013).

- 102 Joehanes, R. *et al.* Integrated genome-wide analysis of expression quantitative trait loci aids interpretation of genomic association studies. *Genome biology* **18**, 16, doi:10.1186/s13059-016-1142-6 (2017).
- 103 Pers, T. H. *et al.* Biological interpretation of genome-wide association studies using predicted gene functions. *Nature communications* **6**, 5890, doi:10.1038/ncomms6890 (2015).

Acknowledgments

The authors thank all investigators, staff members, and study participants for their contribution to all participating studies. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript. The authors received no specific funding for this work. A full list of funding and individual and study acknowledgments appears in the **Supplementary Note**.

Author contributions

Project coordination: I.B.

Writing group: J.C., C.N.S., G.M., A.V., L.J.C., S.C.J.P., K.L.M., C.L., E.W., A.P.M., I.B.

Central analysis group: J.C., C.N.S., G.M., A.V., L.J.C., J.L., S.W., Y.W., X.Z., M.H., T.S.B., R.M., J.W., A.P., R.L., K.H.K.C., J.Y., M.D.A., A.Y.C., A.C., J.H., S.H., M.A.K., T.L., W.M., H.M-M., A.N., S.C.N., K.N., C.K.R., D.R., R.R., D.R., C.S., X.S., L.S., I.D.S., C.A.W., Y.W., P.W., W.Z., J.I.R., A.L.G., M.I.M., J.D., J.B.M., R.A.S., I.P., A.L., C.T.L., S.C.J.P., K.L.M., C.L., E.W., A.P.M., I.B.

Cohort analysts: T.S.A., E.V.R.A., L.F.B., J.A.B., N.P.B., C.P.C., B.E.C., J.C., X.C., L.C., C.C., B.H.C., K.C., Y.C., H.G.d., G.E.D., A.D., Q.D., J.E., S.A.F., J.G., F.G., J.G., S.G., Y.H., F.P.H., J.H., Y.H., T.H., A.H., M.H., R.A.J., T.K., K.A.K., Y.K., M.E.K., I.K.K., S.L., L.A.L., C.D.L., M.L., M.L., S.L., J.L., M.L., J.L., V.L., M.M., C.M., M.E.M., A.N., M.N., D.N., R.N., G.P., M.P., L.R., L.J.R., S.S.R., N.R.R., R.R., K.R., S.S., R.S., K.E.S., B.S., K.S., A.V.S., L.S., T.S., R.J.S., F.T., J.T., S.T., E.v., P.J.v., N.V., M.V., H.W., C.W., N.W., H.R.W., W.W., T.W., A.W., A.R.W., T.X., M.Z., J.Z., W.Z.

Cohort genotyping and phenotyping:

N.A., Z.A., A.A., S.J.L.B., D.B., M.B., R.N.B., A.B., M.B., L.L.B., S.R.B., D.W.B., Q.C., A.C., H.C., Y.C., E.J.C.d., A.D., S.D., G.E., A.F., M.F., C.F., Y.G., A.P.G., A.G., S.H., C.A.H., C.H., A.A.H., C.H., W.A.H., S.I., M.I., M.Arfañl., W.CraigJ., M.E.J., P.K.J., R.R.K., F.R.K., T.K., C.K., W.K., I.K., T.K., J.K., K.L., K.L., D.A.L., N.R.L., R.N.L., H.L., S.L., J.L., A.L., J.L., C.L., T.M., F.M., G.M., S.M., S.M., T.N., G.N.N., J.L.N., M.N., M.J.N., J.M.N., Y.O., A.P., P.A.P., O.P., Q.Q., D.R., D.F.R., A.R., F.R., K.R., I.R., C.S., K.S., N.S., A.S., J.S., H.M.S., K.D.T., T.M.T., B.T., P.RHJ.T., E.T., M.Y.T., A.U., R.M.v., D.v., A.v., J.V.V., J.V., H.V., T.W., K.W., T.Z.

Cohort oversight and/or principal investigator:

G.R.A., L.S.A., C.AlbertoA., M.E.A., P.A., L.A., D.M.B., L.J.B., S.B., H.B., C.B., M.B., E.B., B.O.B., K.B., D.I.B., E.P.B., T.A.B., M.C., M.J.C., J.C.C., D.I.C., Y.C., C.C., F.S.C., A.C., F.C., H.d., G.D., S.E., M.K.E., E.F., L.F., J.C.F., P.W.F., T.M.F., P.F., B.G., M.O.G., P.G., H.G., N.G., S.G., L.G., V.G., X.G., A.H., T.H., C.H., S.R.H., B.L.H., W.H., E.I., P.S.J., M.J., J.B.J., J.WouterJ., P.K., R.K., S.L.R.K., N.K., S.M.K., B.K., M.K., H.A.K., J.S.K., A.K., P.K., D.K., M.K., Z.K., M.L., T.A.L., L.J.L., K.L., H.L., X.L., L.L., C.L., S.L., R.J.F.L., P.KE.M., A.M., A.M., D.O.M., T.A.M., P.B.M., I.N., J.R.O., A.J.O., K.K.O., S.P., C.N.A.P., N.D.P., O.P., C.E.P., D.J.P., P.P.P., M.A.P., B.M.P., L.Q., L.J.R., R.R., S.R., P.M.R., F.R.R., T.E.S., M.S., J.S.N.S., P.S., L.J.S., E.S., P.S., X.S., P.ElineS., K.S.S., B.H.S., H.S., T.S., T.I.A.S., T.D.S., A.S., C.J.S., M.S., L.S., Y.T., E.T., N.J.T., A.T., J.T., T.T., M.U., P.v., C.v., P.V., T.GM.V., L.E.W., M.W., Y.X.W., N.J.W., R.M.W., H.W., W.B.W., A.R.W., G.W., J.F.W., T.W., J.W., A.H.X., L.R.Y., L.Y., M.Y., E.Z., W.Z., A.B.Z., J.I.R., A.L.G., M.I.M., J.D., J.B.M., R.A.S., I.P., A.L., C.L., S.C.J.P., K.L.M., C.L., E.W., A.P.M., I.B.

Competing interests statement

A. Astrup is the recipient of honoraria as speaker for a wide range of Danish and international concerns and receives royalties from textbooks, and from popular diet and cookery books. A. Astrup is also co-inventor of a number of patents, including Methods of inducing weight loss, treating obesity and preventing weight gain (licensee Gelesis, USA) and Biomarkers for predicting degree of weight loss (licensee Nestec SA, CH), owned by the University of Copenhagen, in accordance with Danish law. I. Barroso and spouse own stock in GlaxoSmithKline and Incyte Corporation. B.H. Chen is now an employee of Life Epigenetics, Inc.; all work was completed prior to employment at Life Epigenetics. A.Y. Chu is now an employee of Merck & Co.; all work was completed prior to employment by Merck & Co. J.C. Florez has received consulting honoraria from Janssen. J. Gayan is now an employee of F. Hoffmann-La Roche Ltd, and owns stock of Roche and GlaxoSmithKline. A.L. Gloyn has received honoraria from Merck and Novo Nordisk. As of June 2019, ALG discloses that her spouse is an employee of Genentech and hold stock options in Roche. E. Ingelsson is now an employee of GSK; all work was completed prior to his employment by GSK. W. März has received grants and/or personal fees from the following companies/corporations: Siemens Healthineers, Aegerion Pharmaceuticals, AMGEN, Astrazeneca, Sanofi, Alexion Pharmaceuticals, BASF, Abbott Diagnostics Numares AG, Berlin-Chemie, Akzea Therapeutics, Bayer Vital GmbH, bestbion dx GmbH, Boehringer Ingelheim Pharma GmbH Co KG, Immundiagnostik GmbH, Merck Chemicals GmbH, MSD Sharp and Dohme GmbH, Novartis Pharma GmbH, Olink Proteomics, and Synlab Holding Deutschland GmbH. M.I. McCarthy has served on advisory panels for Pfizer, NovoNordisk, Zoe Global and received honoraria from Merck, Pfizer, NovoNordisk and Eli Lilly. He holds stock options in Zoe Global and has received research funding from Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, NovoNordisk, Pfizer, Roche, Sanofi Aventis, Servier, Takeda. He is now an employee of Genentech and a holder of Roche stock. J.B. Meigs has consulted for Quest Diagnostics, Inc., who manufacturers of an HbA1c assay. M.E. Montasser has received grant funding from Regeneron Pharmaceuticals. M.E. Montasser is also an inventor on a patent that was published by the United States Patent and Trademark Office on December 6, 2018 under Publication Number US 2018-0346888, and international patent application that was published on December 13, 2018 under Publication Number WO-2018/226560; all work was completed before these COI arose, and are unrelated to this work. D. Mook-Kanamori is a part-time clinical research consultant for Metabolon. J.L. Nadler is a member of the Scientific Advisory Board for Veralox Therapeutics Inc. C.N.A. Palmer has received research support from GlaxoSmithKline and AstraZeneca unrelated to this project. B.M. Psaty serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. N. Sattar has consulted for Astrazeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Napp and Sanofi and received grant support from Boehringer Ingelheim. R.A. Scott is an employee and shareholder of GlaxoSmithKline. T. Spector is the founder of Zoe Global Ltd. J. Tuomilehto receives research support from Bayer, is a consultant for Eli Lilly, and holds stock in Orion Pharma and Aktivolabs Ltd.

Figure Legends

Figure 1 - Summary of all 242 loci identified in this study. 235 trans-ancestry loci are shown in orange (novel) or black (established) along with seven single-ancestry loci (blue) represented by nearest gene. Each locus is mapped to corresponding chromosome (outer segment). Each set of rows shows the results from the trans-ancestry analysis (orange) and each of the ancestries: European (purple), African American (tan), East Asian (grey), South Asian (green), Hispanic (yellow), sub-Saharan African (Ugandan-pink). Loci with a corresponding type 2 diabetes signal are represented by red circles in the middle of the plot.

Figure 2 – Trait variance explained by associated loci. The boxplots show the maximum, first quartile, median, third quartile and minimum of trait variance explained when using a genetic score with single-ancestry lead and index variants (EUR, AA, EAS, HISP and SAS) or a combination of individual trait trans-ancestry lead variants and single-ancestry lead and index variants (TA+EUR,

TA+AA, TA+EAS, TA+HISP and TA+SAS). Variance explained for each trait (FG, FI and HbA1c) in each ancestry is shown on different panels and in different colors. R^2 was estimated in 1 to 11 cohorts with sample sizes ranging from 489 to 9,758 (**Supplementary Tables 8-11**).

Figure 3 – Transferability of PGS across ancestries. For each trait, the barplots represent trait variance explained when using a European ancestry-derived PGS in European, East Asian and African American test datasets. Variance explained (the height of each bar) for each trait (FG, FI and HbA1c) in each ancestry is shown on different panels and in different colors.

Figure 4 - Trans-ancestry fine-mapping. A) Number of plausible causal variants at each locus-trait association derived from FINEMAP. B) Number of variants within each 99% credible set. Twenty-one locus-trait associations at 19 loci were mapped to a single variant in the 99% credible set. C) Fine-mapping resolution. For each of the 98 locus-trait associations with a predicted single causal variant in both trans-ancestry and single-ancestry analyses, the number of variants included in the 99% credible set in the single-ancestry fine-mapping (x axis; logarithmic scale) is plotted against those in the trans-ancestry fine-mapping (y axis; logarithmic scale). Trans-ancestry and single-ancestry fine-mapping were based on the same set of variants. After removing eight locus-trait associations with one variant in the 99% credible sets in both trans-ancestry and single-ancestry analyses, there were 18 locus-trait associations (in grey) where trans-ancestry fine-mapping did not improve the resolution of fine-mapping results (i.e. number of variants in the 99% credible set did not decrease). Of the 72 locus-trait associations with improved trans-ancestry fine-mapping resolution (blue and red) further analyses in European fine-mapping emulating the total sample size in trans-ancestry fine-mapping demonstrated that 34 locus-trait associations (in red) were improved because of both total sample size and differences across ancestries, while 38 locus-trait associations (in blue) were only improved due to increased sample size in the original trans-ancestry fine-mapping analysis.

Figure 5 - Epigenomic landscape of trait-associated variants. A: Enrichment of GWAS variants to overlap genomic regions including ‘Static Annotations’ which are common or ‘static’ across cell types and ‘Stretch Enhancers’ which are identified in each tissue/cell type. The numbers of signals for each trait are indicated in parentheses. Enrichment was calculated using GREGOR⁵⁶. One-sided test for significance (red) is determined after Bonferroni correction to account for 59 total annotations tested for each trait; nominal significance ($P < 0.05$) is indicated in yellow. B: Enrichment for HbA1c GWAS signals partitioned into “hard” Glycemic and Red Blood Cell cluster (signals from “hard” mature Red Blood Cell and reticulocyte clusters together) to overlap annotations including StrEs in Islets and the blood-derived leukemia cell line K562, respectively (additional partitioned results in **Supplementary Table 17**). C: Individual FI GWAS signals that drive enrichment in Adipose and Skeletal Muscle StrEs. D, E: Genome browser shots of FI GWAS signals – intronic region of the *COL4A2* gene (D) and an inter-genic region ~25kb from *LINC01214* gene (E) showing GWAS SNPs (lead and LD $r^2 > 0.8$ proxies), ATAC-seq signal tracks and chromatin state annotations in different tissues/cell types.

Figure 6 - Tissues and cell types significantly enriched for genes within glycemic-associated loci. Top panel FG-associated loci, middle panel FI-associated loci, bottom panel HbA1c-associated loci. FDR thresholds are shown in red ($q < 0.05$), orange ($q < 0.2$), grey ($q \geq 0.2$).

Figure 7 - Gene-set enrichment analyses. Results from affinity-propagation clustering of significantly enriched gene-sets ($FDR < 0.05$) identified by DEPICT for A) FG, B) FI, and C) HbA1c. Each node is a cluster of gene-sets represented by an exemplar gene-set with similarities between the clusters represented by the Pearson correlation coefficients ($r > 0.3$). The nodes are colored according to the minimum gene-set enrichment p-value for gene-sets in that cluster. Example clusters are expanded to show the contributing gene-sets.

Tables

Table 1 – Glossary of terms - This study combined analyses of trait-associations across multiple correlated glycemic traits and across multiple ancestries, which has presented challenges in our ability to apply commonly used terms with clarity. For this reason, we define below terms often used in the field with variable meaning, as well as definitions of new terms used in this study.

Term	Definition
EA (Effect allele)	The effect allele was that defined by METAL based on trans-ancestry FG results and aligned such that the same allele was kept as the effect allele across all ancestries and traits, irrespective of its allele frequency or effect size for that particular ancestry and trait, in this way the effect allele is not necessarily the trait-increasing allele.
Single-ancestry lead variant	Variant with the smallest p-value amongst all with $P < 5 \times 10^{-8}$, within a 1Mb region, based on analysis of a single trait in a single ancestry.
Single-ancestry index variants	Variants identified by GCTA analysis of each autosome, and that appear to exert conditionally distinct effects on a given trait in a given ancestry ($P < 5 \times 10^{-8}$). As defined, these include the single-ancestry lead variants.
Trans-ancestry lead variant	Variant identified by trans-ethnic meta-analysis of a given trait that has the strongest association for that trait ($\log_{10}BF > 6$, which is broadly equivalent to $P < 5 \times 10^{-8}$) within a 1Mb region.
Single-ancestry locus	1Mb region centred on a single-ancestry lead variant which does not contain a lead variant identified in the trans-ancestry meta-analysis (i.e., does not contain a trans-ancestry lead variant).
Signal	Conditionally independent association between a trait and a set of variants in LD with each other and which is noted by the corresponding index variant.
Trans-ancestry locus	A genomic interval that contains trans-ancestry trait-specific lead variants, with/out additional single-ancestry index variants, for one or more traits. This region is defined by starting at the telomere of each chromosome and selecting the first single-ancestry index variant or trans-ancestry lead variant for any trait. If other trans-ancestry lead variants or single-ancestry index variants mapped within 500kb of the first signal, then they were merged into the same locus. This process was repeated until there were no more signals within 500kb of the previous variant. A 500kb interval was added to the beginning of the first signal, and the end of the last signal to establish the final boundary of the trans-ancestry locus (Extended Data Figure 2). As defined, a trans-ancestry locus may not have a single lead trans-ancestry variant, but may instead contain multiple trans-ancestry lead variants, one for each trait.

Online Methods

Study design and participants

This study included trait data from four glycemic traits: fasting glucose (FG), fasting insulin (FI), 2hr post-challenge glucose (2hGlu), and glycated hemoglobin (HbA1c). The total number of contributing cohorts ranged from 41 (2hGlu) to 131 (FG), and the maximum sample size for each trait ranged from 85,916 (2hGlu) to 281,416 (FG) (**Supplementary Table 1**). Overall, European ancestry (EUR) participants dominated the sample size for all traits, representing between 68.0% (HbA1c) to 73.8% (2hGlu) of the overall sample size. African Americans (AA) represented between 1.7% (2hGlu) to 5.9% (FG) of participants; individuals of Hispanic ancestry (HISP) represented between 6.8% (FG) to 14.6% (2hGlu) of participants; individuals of East-Asian ancestry (EAS) represented between 9.9% (2hGlu) to 15.4% (HbA1c) of participants; and South-Asian ancestry (SAS) individuals represented between 0% (no contribution to 2hGlu) to 4.4% (HbA1c) of participants. Data from Ugandan participants were only available for the HbA1c analysis and represented 2% of participants.

Phenotypes

Analyses included data for FG and 2hGlu measured in mmol/l, FI measured in pmol/l, and HbA1c in % [where possible, studies reported HbA1c as a National Glycohemoglobin Standardization Program (NGSP) percent]. Similar to previous MAGIC efforts⁷, individuals were excluded if they had type 1 or type 2 diabetes (defined by physician diagnosis); reported use of diabetes-relevant medication(s); or had a FG ≥ 7 mmol/L, 2hGlu ≥ 11.1 mmol/L, or HbA1c $\geq 6.5\%$, as detailed in **Supplementary Table 1**. 2hGlu measures were obtained 120 minutes after a glucose challenge in an oral glucose tolerance test (OGTT). Measures for FG and FI taken from whole blood were corrected to plasma level using the correction factor 1.13⁸⁰.

Genotyping, quality control, and imputation

Each participating cohort performed study-level quality control, imputation, and association analyses following a shared analysis plan. Cohorts were genotyped using commercially available genome-wide arrays or the Illumina CardioMetabochip (Metabochip) array (**Supplementary Table 1**)⁸¹. Prior to imputation, each cohort performed stringent sample and variant quality control (QC) to ensure only high-quality variants were kept in the genotype scaffold for imputation. Sample quality control checks included removing samples with low call rate $< 95\%$, extreme heterozygosity, sex mismatch with X chromosome variants, duplicates, first- or second-degree relatives (unless by design), or ancestry outliers. Following sample QC, cohorts applied variant QC thresholds for call rate ($< 95\%$), Hardy-Weinberg Equilibrium (HWE) $P < 1 \times 10^{-6}$, and minor allele frequency (MAF). Full details of QC thresholds and exclusions by participating cohort are available in **Supplementary Table 1**.

Imputation was performed up to the 1000 Genomes Project phase 1 (v3) cosmopolitan reference panel⁸², with a small number of cohorts imputing up to the 1000 Genomes phase 3 panel¹⁹ or population-specific reference panels (**Supplementary Table 1**).

Study level association analyses

Each of the glycemic traits (FG, natural log FI, and 2hGlu) were regressed on BMI (except HbA1c), study-specific covariates, and principal components (unless implementing a linear mixed model). Analyses for FG, FI, and 2hGlu were adjusted for BMI as we had previously shown this did not materially affect results for FG and 2hGlu but improved our ability to detect FI-associated loci¹⁵. For simplicity, we refer to the traits as FG, FI and 2hGlu. For a discussion on collider bias see **Supplementary Note section 2c**. Both the raw and rank-based inverse normal transformed residuals from the regression were tested for association with genetic variants using SNPTTEST²³ or Mach2Qtl^{83,84}. Poorly imputed variants, defined as imputation $r^2 < 0.4$ or INFO score < 0.4 , were excluded from downstream analyses (**Supplementary Table 1**). Following study level QC,

approximately 12,229,036 variants (GWAS cohorts) and 1,999,204 variants (Metabochip cohorts) were available for analysis (**Supplementary Table 1**).

Centralized quality control

Each contributing cohort shared their summary statistic results with the central analysis group who performed additional QC using EasyQC⁸⁵. Allele frequency estimates were compared to estimates from 1000Gp1 reference panel⁸², and variants were excluded from downstream analyses if there was a minor allele frequency difference > 0.2 for AA, EUR, HISP, and EAS populations against AFR, EUR, MXL, and ASN populations from 1000 Genomes Phase 1, respectively, or a minor allele frequency difference > 0.4 for SAS against EUR populations. At this stage, additional variants were excluded from each cohort file if they met one of the following criteria: were tri-allelic; had a minor allele count (MAC) < 3 ; demonstrated a standard error of the effect size ≥ 10 ; or were missing an effect estimate, standard error, or imputation quality. All data that survived QC (approximately 12,186,053 variants from GWAS cohorts and 1,998,657 variants from Metabochip cohorts) were available for downstream meta-analyses.

Single-ancestry meta-analyses

Single-ancestry meta-analyses were performed within each ancestry group using the fixed-effects inverse variance meta-analysis implemented in METAL²⁰. We applied a double-genomic control (GC) correction^{15,86} to both the study-specific GWAS results and the single-ancestry meta-analysis results. Study-specific Metabochip results were GC-corrected using 4,973 SNPs included on the Metabochip array for replication of associations with QT-interval, a phenotype not correlated with our glycemic traits¹⁵.

Identification of single-ancestry index variants

To identify distinct association index variants across each chromosome within each ancestry (**Table 1**), we performed approximate conditional analyses implemented in GCTA²¹ using the `--cojo-slc` option (autosomes) and distance-based clumping (X chromosome). Linkage disequilibrium (LD) correlations for GCTA were estimated from a representative cohort from each ancestry: WGHS (EUR); CHNS (EAS); SINDI (SAS); BioMe (AA); SOL (HISP) and Uganda (for itself). The results from GCTA were comparable when using alternative cohorts for the LD reference. For any index variant with a QC flag which caused reason for concern, we performed manual inspection of forest plots to decide whether the signal was likely to be real (**Supplementary note**). Among 335 single-ancestry index variants across all traits, this manual inspection was done for 40 signals of which 32 passed and 8 failed after inspection. Thus, a total of 327 single-ancestry index variants passed and 8 failed.

Trans-ancestry meta-analyses

To leverage power across all ancestries, we also conducted trait-specific trans-ancestry meta-analysis by combining the single-ancestry meta-analysis results using MANTRA (**Supplementary note**)⁸⁷. We defined $\log_{10}$ Bayes' Factor (BF) > 6 as genome-wide significant, approximately comparable to $P < 5 \times 10^{-8}$.

Manual curation of trans-ancestry lead variants

To ensure trans-ancestry lead variants were robust, we performed manual inspection of forest plots by at least two authors, for any variants with flags indicating possible QC issues (**Supplementary note**). Of 463 trans-ancestry lead variants across all traits, 184 passed without inspection, 131 passed after inspection, and 148 failed after inspection.

Correlation in EAF and heterogeneity in effect sizes of TA lead variants across ancestries

For each pair of ancestries, we calculated Pearson's correlation in EAFs for each trans-ancestry lead variant. The pairwise summarized heterogeneity of effect sizes between ancestries was then tested

using the joint F-test of heterogeneity³². The test statistic is the sum of Cochran Q-statistics for heterogeneity across all trans-ancestry signals. Under the null hypothesis, the statistics follows the χ^2 distribution with n degrees of freedom, where n is the number of the trans-ancestry lead variants.

LD-pruned variant lists

Several downstream analyses (for example, genomic feature enrichment, genetic scores, and estimation of variance explained by associated variants) require independent LD-pruned variants ($r^2 < 0.1$) to avoid double-counting variants which might otherwise be in LD with each other and that do not provide additional “independent” evidence. Therefore, for these analyses we generated different lists of either TA or single-ancestry LD pruned ($r^2 < 0.1$) variants, keeping in each case the variant with the strongest evidence of association (**Supplementary Table 7**). Subsequently, we combined TA and single-ancestry variant lists and conducted further LD pruning. For some analyses, we took the TA pruned variant list and added single-ancestry signals if the LD $r^2 < 0.1$, while for others we started with the single-ancestry pruned lists and supplemented with TA lead variants if the LD $r^2 < 0.1$. One exception was the list used for eQTL co-localizations, which included all single-ancestry European signals (without LD pruning) and supplemented with any additional TA lead variants (starting from the variants with the most significant P-values) in EUR LD $r^2 < 0.1$ with any of the variants already in list, and that reached at least $P < 1 \times 10^{-5}$ in the European ancestry meta-analysis.

Trait variance explained by associated loci

To determine how much of the phenotypic variance of each trait could be explained by the corresponding trait-associated loci, variants were combined in a series of weighted genetic scores (GS). The analysis was performed in a subset of the cohorts included in the discovery GWAS (with representation from each ancestry) and in a smaller number of independent cohorts (European ancestry only). Up to three different GS were derived per trait (and for each ancestry) in order to evaluate the potential for the trans-ancestry meta-GWAS identified loci to provide additional information above and beyond that contributed by the ancestry-specific meta-analysis results. These GS comprised: List A - single-ancestry signals; List B - single-ancestry signals plus trans-ancestry signals; and List C - trans-ancestry signals plus single-ancestry signals (**Supplementary Table 7**). In the case of the European ancestry cohorts that contributed to the GWAS, we employed the method of Nolte *et al.*³³ to adjust the effect sizes (betas) from the GWAS for the contribution of that cohort, providing sets of cohort-specific effect sizes that were then used to generate the GS. The association between each GS and its corresponding trait was tested by linear regression and the adjusted R^2 from the model extracted as an estimate of the variance explained.

Transferability of European ancestry-derived polygenic scores (PGS) across ancestries

We used the PRS-CSauto³⁴ software to first build European ancestry-derived PGS for each glycemic trait (FG, FI, 2hGlu, HbA1c) on the basis of summary statistics. However, PRS-CSauto does not perform well when the training dataset is relatively small and the genetic architecture is sparse³⁴. Consequently, 2hGlu was excluded from this analysis. For each trait, to obtain European ancestry training and test datasets, we first removed all cohorts only genotyped on the Metabochip which were not included in this analysis. From the remaining cohorts we then removed five of the largest European cohorts contributing to the respective European ancestry meta-analysis. For each trait, these five cohorts were meta-analyzed and used as the European ancestry test dataset. Subsequently, the remaining European ancestry cohorts were also meta-analyzed and used as the European ancestry training dataset. For each of the other ancestries, cohorts only genotyped on the Metabochip were also removed, and the remaining cohorts were meta-analyzed, and used as the non-European ancestry test datasets. Variants with MAF < 0.05 or missing in over half of the individuals in the training dataset were removed^{34,88}. The PGS for each trait was built using PRS-CSauto with default settings³⁴ with the effect size estimates based on the European training dataset

being revised based on an LD reference panel matching the test dataset. The proportion of the trait variance explained by the European ancestry-derived PGS (R^2) was estimated using the R package “gtx”⁸⁹ based on the revised effect sizes and summary statistics from the test dataset for each ancestry.

Fine-mapping

Of the 242 loci identified in this study, 237 were autosomal loci which we took forward for fine-mapping (**Supplementary Table 2**). We used the Bayesian fine-mapping method FINEMAP⁹⁰ (version 1.1) to refine association signals and attempt to identify likely causal variants at each locus. FINEMAP estimates the maximum number of causal variants at each locus, calculates the posterior probability of each variant being causal, and proposes the most likely configuration of causal variants. The posterior probabilities of the configurations in each locus were used to construct 99% credible sets.

We performed both single-ancestry and trans-ancestry fine-mapping. In both analyses, only data from cohorts genotyped on GWAS arrays were used, and analyses were limited to trans-ancestry lead variants and other single-ancestry lead variants present in at least 90% of the samples for each trait. For the single-ancestry fine-mapping, FINEMAP estimates the number of causal variants in a region up to a maximum number, which we set to be two plus the number of distinct signals identified from the GCTA signal selection. FINEMAP uses single-ancestry and trait-specific z-scores from the fixed-effect meta-analysis in METAL²⁰ and an ancestry-specific LD reference, which we created from a subset of cohorts (combined sample size > 30% of the sample size for that ancestry), weighting each cohort by sample size. In the trans-ancestry fine-mapping, FINEMAP was similarly used to estimate the number of causal variants starting with two, and trait-specific z-scores and LD maps were generated from the sample size weighted average of those used in the single-ancestry fine-mapping. The maximum number of causal variants was iteratively increased by one until it was larger than the number of causal variants supported by data (Bayes factor), which was the estimated maximum number of causal variants used in the final run of fine-mapping analysis.

To compare fine-mapping results obtained from the single-ancestry and trans-ancestry efforts, analyses were limited to fine-mapping regions with evidence for a single likely causal variant in both, enabling a straightforward comparison of credible sets (**Supplementary note**). To ensure any difference in the fine-mapping results was not driven by different sets of variants being present in the different analyses, we repeated the single-ancestry fine-mapping limited to the same set of variants used in the trans-ancestry fine-mapping. The fine-mapping resolution was assessed based on comparisons of the 99% credible sets in terms of number of variants included in the set, and length of the region. To assess whether the improvement in the trans-ancestry fine-mapping was due to differences in LD, increased sample size, or both, we repeated the trans-ancestry fine-mapping mimicking the sample size present in the single-ancestry fine-mapping by dividing the standard errors by the square root of the sample size ratio and compared the results with those from the single-ancestry fine-mapping.

Functional Annotation of trait-associated variants

HbA1c signal classification

There were 218 HbA1c-associated signals from either the single-ancestry (i.e. all GCTA-signals from any ancestry) or trans-ancestry meta-analyses. To classify these signals in terms of their likely mode of action (i.e., glycemic, erythrocytic, or other⁷), we examined association summary statistics for the lead variants at the 218 signals in other large European datasets for 19 additional traits: three glycemic traits from this study (FG, 2hGlu and FI); seven mature red blood cell (RBC) traits^{91,92} (red

blood cell count, mean corpuscular volume, hematocrit, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, hemoglobin concentration and red cell distribution width); five reticulocyte traits (reticulocyte count, reticulocyte fraction of red cells, immature fraction of reticulocytes, high light scatter reticulocyte count and high light scatter percentage of red cells)^{91,92}, and four iron traits (serum iron, transferrin, transferrin saturation and ferritin)⁹³. Of the 218 HbA1c signals, data were available for the lead (n=183) or proxy (European LD $r^2 > 0.8$, n = 8) variants at 191 signals.

The additional traits were clustered using hierarchical clustering to ensure biologically related traits would cluster together (**Supplementary note**). We then used a non-negative matrix factorization (NMF)⁹⁴ process to cluster the HbA1c signals. Each cluster was labelled as glycemic, reticulocyte, mature RBC, or iron related based on the strength of association of signals in the cluster to the glycemic, reticulocyte, mature RBC and iron traits (**Supplementary note**). To verify that our cluster naming was correct, we used HbA1c association results conditioned on either FG or iron traits, or type 2 diabetes association results (**Supplementary note**).

HbA1c genetic risk scores (GRSs) and type 2 diabetes (T2D) risk

We constructed GRS for each cluster of HbA1c-associated signals (based on hard clustering) and tested the association of each cluster with T2D risk using samples from the UK Biobank. Pairs of HbA1c signals in LD (EUR $r^2 > 0.10$) were LD pruned by removing the signal with the less significant *P*-value of association with HbA1c. The GRS for each cluster was calculated based on the logarithm of odds ratios from the latest T2D study summary statistics⁹⁵ and UK Biobank genotypes imputed to the Haplotype Reference Consortium¹⁹. From 487,409 UK Biobank samples (age between 46 and 82 years, and 55% female), we excluded participants for the following reasons: 373 with mismatched sex; 9 not used in the kinship calculation; 78,365 non-European ancestry individuals; and 138,504 with missing T2D status, age, or sex information. We further removed 26,896 related participants (kinship > 0.088, preferentially removing individuals with the largest number of relatives and controls where a T2D case was related to a control). T2D cases were defined by: (i) a history of diabetes without metformin or insulin treatment, (ii) self-reported diagnosis of T2D, or (iii) diagnosis of T2D in a national registry (N = 17,022, age between 47 and 79 years, and 36% female). Controls were participants without a history of T2D (N = 226,240, age between 46 and 82 years, and 56% female). We tested for association between each GRS and T2D using logistic regression including covariates for age, sex, and the first five principal components. Significance of association was evaluated by a bootstrap approach to incorporate the variance of each HbA1c associated signal in the T2D summary data. To do this, we generated the GRS of each cluster 200 times by resampling the logarithm of odds ratio of each signal with T2D. For each non-glycemic class that had a GRS significantly associated with T2D, we performed sensitivity analyses to evaluate whether the association was driven from variants that also belonged to a glycemic cluster when using a soft clustering approach (the signals were classified as also glycemic in the soft clustering or had an association $P \leq 0.05$ with any of the three glycemic traits).

Chromatin states

To identify genetic variants within association signals that overlapped predicted chromatin states, we used a previously published, 13 chromatin state model that included 31 diverse tissues, including pancreatic islets, skeletal muscle, adipose, and liver³⁹. Briefly, this model was generated from cell/tissue ChIP-seq data for H3K27ac, H3K27me3, H3K36me3, H3K4me1, and H3K4me3, and input control from a diverse set of publicly available data^{53,57,96,97} using the ChromHMM program⁹⁸. As reported previously³⁹, StrEs were defined as contiguous enhancer chromatin state (Active Enhancer 1 and 2, Genic Enhancer and Weak Enhancer) segments longer than 3kb⁵⁷.

Enrichment of genetic variants in genomic features

We used GREGOR (version 1.2.1) to calculate the enrichment of GWAS variants overlapping static and StrEs⁵⁶. For calculating the enrichment of glycemic trait-associated variants in these annotations, we used the filtered list of trait-associated variants as described above (**Supplementary Table 7**) as input. For calculating the enrichment of sub-classified HbA1c variants, we included the list of loci characterized as Glycemic, another list of loci characterized as Reticulocyte or mature Red Blood Cell, collectively representing the red blood cell fraction, along with lists of iron related or unclassified loci (**Supplementary Table 17**). We used the following parameters in GREGOR enrichment analyses: European r^2 threshold (for inclusion of variants in LD with the lead variant) = 0.8, LD window size = 1 Mb, and minimum neighbour number = 500.

We used fGWAS (version 0.3.6)⁵⁸ to calculate enrichment of glycemic trait-associated variants in static and StrE annotations using summary level GWAS results. We used the default fGWAS parameters for enrichment analyses for individual annotations for each trait. For each annotation, the model provided the natural log of maximum likelihood estimate of the enrichment parameter. Annotations were considered as significantly enriched if the log2 (parameter estimate) and respective 95% confidence intervals were above zero or significantly depleted if the log2 (parameter estimate) and respective 95% confidence intervals were below zero.

We tested enrichment of trait-associated variants in static and StrE annotations with GARFIELD (v2)⁵⁹. We formatted annotation overlap files as required by the tool; prepared input data at two GWAS thresholds - of 1×10^{-5} and a more stringent 1×10^{-8} by pruning and clumping with default parameters (garfield-prep-chr script). We calculated enrichment in each individual annotation using garfield-test.R with -c option set to 0. We also calculated the effective number of annotations using the garfield-Meff-Padj.R script. We used the effective number of annotations for each trait to obtain Bonferroni corrected significance thresholds for enrichment for each trait.

eQTL analyses

To aid in the identification of candidate casual genes at the European-only and trans-ancestry association signals, we examined whether any of the lead variants associated with glycemic traits (**Supplementary Table 7**) were also associated with expression level (FDR < 5%) of nearby transcripts located within 1 Mb in existing eQTL data sets of blood, subcutaneous adipose, visceral adipose, skeletal muscle, and pancreatic islet samples^{60,61,99-102}. LD was estimated from the collected cohort pairwise LD information, where available, else from the European samples in 1000G phase 3. GWAS and eQTL signals likely co-localize when the GWAS variant and the variant most strongly associated with the expression level of the corresponding transcript (eSNP) exhibit high pairwise LD ($r^2 > 0.8$; 1000 Genomes Phase 3, EUR). At these signals, we conducted reciprocal conditional analyses to test association between the GWAS variant and transcript level when the eSNP was also included in the model, and vice versa. We report GWAS and eQTL signals as co-localized if the association for the eSNP was not significant (FDR $\geq 5\%$) when conditioned on the GWAS variant; we also report signals from the eQTLGen whole blood meta-analysis data that meet only the LD threshold because conditional analysis was not possible.

Tissue and gene-set analysis

We performed enrichment analysis using DEPICT (Data-driven Expression-Prioritized Integration for Complex Traits) version 3, specifically developed for 1000 Genomes Project imputed meta-analysis data¹⁰³ to identify cell types and tissues in which genes at trait-associated variants were strongly expressed, and to detect enrichment of gene-sets or pathways. DEPICT data included human gene expression data for 19,987 genes in 10,968 reconstituted gene sets, and 209 tissues/cell types. Because gene expression data in DEPICT is based on European samples and LD, we selected trait-associated variants with $P < 10^{-5}$ in the European meta-analysis and tested for enrichment of signals in each reconstituted gene-set, and each tissue or cell type. Enrichment results with a false discovery

rate (FDR)<0.05 were considered significant. We ran DEPICT based on association results for all traits among: (i) cohorts with genome-wide data, or (ii) all cohorts (genome-wide and Metabochip cohorts). Because results were broadly consistent between the two approaches, we present results from the analysis that contained all cohorts as it had greater statistical power.

Statistics and reproducibility

Sample size

No statistical method was used to predetermine sample size. We aimed to bring together the largest possible sample size with GWAS data from individuals of diverse ancestries (European, Hispanic, African American, East Asian, South Asian and sub-Saharan African) without diabetes and with data for one or more of the following traits: fasting glucose, fasting insulin, 2hr post-challenge glucose, and glycated hemoglobin. The sample sizes were 281,416 (FG), 213,650 (FI), 215,977 (HbA1c) and 85,916 (2hGlu) (**Supplementary Table 1**). Our sample size was sufficiently powered to detect common variant associations with each of the glycemic traits and was able to detect associations at 242 loci.

Randomization/ Blinding

This is a study of continuous traits therefore there were no experiments to randomize and there was no “outcome” to which investigators needed to be blinded to.

Data exclusions

Prior to conducting this study, we identified reasons for which data should be excluded from the analysis at either the cohort or summary level; these exclusions are as follows. Sample quality control checks included removing samples with low call rate < 95%, extreme heterozygosity, sex mismatch with X chromosome variants, duplicates, first- or second-degree relatives (unless by design), or ancestry outliers. Following sample QC, cohorts applied variant QC thresholds for call rate (< 95%), Hardy-Weinberg Equilibrium (HWE) $P < 1 \times 10^{-6}$, and minor allele frequency (MAF). Full details of QC thresholds and exclusions by participating cohort are available in **Supplementary Table 1**. Each contributing cohort shared their summary statistic results with the central analysis group who performed additional QC using EasyQC. Allele frequency estimates were compared to estimates from 1000Gp1 reference panel, and variants were excluded from downstream analyses if there was a minor allele frequency difference > 0.2 for AA, EUR, HISP, and EAS populations against AFR, EUR, MXL, and ASN populations from 1000 Genomes Phase 1, respectively, or a minor allele frequency difference > 0.4 for SAS against EUR populations. At this stage, additional variants were excluded from each cohort file if they met one of the following criteria: were tri-allelic; had a minor allele count (MAC) < 3; demonstrated a standard error of the effect size ≥ 10 ; imputation $r^2 < 0.4$ or INFO score < 0.4; or were missing an effect estimate, standard error, or imputation quality.

Data Availability

Ancestry-specific and overall meta-analysis summary level results are available through the MAGIC website (<https://www.magicinvestigators.org/>). Summary statistics are also available through the GWAS catalogue (<https://www.ebi.ac.uk/gwas/>) with the following accession codes: GCST90002225, GCST90002226, GCST90002227, GCST90002228, GCST90002229, GCST90002230, GCST90002231, GCST90002232, GCST90002233, GCST90002234, GCST90002235, GCST90002236, GCST90002237, GCST90002238, GCST90002239, GCST90002240, GCST90002241, GCST90002242, GCST90002243, GCST90002244, GCST90002245, GCST90002246, GCST90002247, and GCST90002248.

References for Methods

1719 80 D'Orazio, P. *et al.* Approved IFCC recommendation on reporting results for blood
1720 glucose (abbreviated). *Clinical chemistry* **51**, 1573-1576,
1721 doi:10.1373/clinchem.2005.051979 (2005).

1722 81 Voight, B. F. *et al.* The metabochip, a custom genotyping array for genetic studies of
1723 metabolic, cardiovascular, and anthropometric traits. *PLoS genetics* **8**, e1002793,
1724 doi:10.1371/journal.pgen.1002793 (2012).

1725 82 Abecasis, G. R. *et al.* An integrated map of genetic variation from 1,092 human
1726 genomes. *Nature* **491**, 56-65, doi:10.1038/nature11632 (2012).

1727 83 Li, Y., Willer, C. J., Ding, J., Scheet, P. & Abecasis, G. R. MaCH: using sequence and
1728 genotype data to estimate haplotypes and unobserved genotypes. *Genetic
1729 epidemiology* **34**, 816-834, doi:10.1002/gepi.20533 (2010).

1730 84 Pei, Y. F., Zhang, L., Li, J. & Deng, H. W. Analyses and comparison of imputation-
1731 based association methods. *PloS one* **5**, e10827, doi:10.1371/journal.pone.0010827
1732 (2010).

1733 85 Winkler, T. W. *et al.* Quality control and conduct of genome-wide association meta-
1734 analyses. *Nature protocols* **9**, 1192-1212, doi:10.1038/nprot.2014.071 (2014).

1735 86 Devlin, B. & Roeder, K. Genomic control for association studies. *Biometrics* **55**, 997-
1736 1004 (1999).

1737 87 Morris, A. P. Transethnic meta-analysis of genomewide association studies. *Genetic
1738 epidemiology* **35**, 809-822, doi:10.1002/gepi.20630 (2011).

1739 88 Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from
1740 polygenicity in genome-wide association studies. *Nature genetics* **47**, 291-295,
1741 doi:10.1038/ng.3211 (2015).

1742 89 Dastani, Z. *et al.* Novel loci for adiponectin levels and their influence on type 2
1743 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals.
1744 *PLoS genetics* **8**, e1002607, doi:10.1371/journal.pgen.1002607 (2012).

1745 90 Benner, C. *et al.* FINEMAP: efficient variable selection using summary data from
1746 genome-wide association studies. *Bioinformatics (Oxford, England)* **32**, 1493-1501,
1747 doi:10.1093/bioinformatics/btw018 (2016).

1748 91 Astle, W. J. *et al.* The Allelic Landscape of Human Blood Cell Trait Variation and Links
1749 to Common Complex Disease. *Cell* **167**, 1415-1429.e1419,
1750 doi:10.1016/j.cell.2016.10.042 (2016).

1751 92 Canela-Xandri, O., Rawlik, K. & Tenesa, A. An atlas of genetic associations in UK
1752 Biobank. *Nature genetics* **50**, 1593-1599, doi:10.1038/s41588-018-0248-z (2018).

1753 93 Benyamin, B. *et al.* Novel loci affecting iron homeostasis and their effects in
1754 individuals at risk for hemochromatosis. *Nature communications* **5**, 4926,
1755 doi:10.1038/ncomms5926 (2014).

1756 94 Binesh, N. & Rezghi, M. Fuzzy clustering in community detection based on
1757 nonnegative matrix factorization with two novel evaluation criteria. *Applied Soft
1758 Computing* **69**, 689-703 (2018).

1759 95 Scott, R. A. *et al.* An Expanded Genome-Wide Association Study of Type 2 Diabetes in
1760 Europeans. *Diabetes* **66**, 2888-2902, doi:10.2337/db16-1253 (2017).

1761 96 Ernst, J. *et al.* Mapping and analysis of chromatin state dynamics in nine human cell
1762 types. *Nature* **473**, 43-49, doi:10.1038/nature09906 (2011).

1763 97 Mikkelsen, T. S. *et al.* Comparative epigenomic analysis of murine and human
1764 adipogenesis. *Cell* **143**, 156-169, doi:10.1016/j.cell.2010.09.006 (2010).

1765 98 Ernst, J. & Kellis, M. ChromHMM: automating chromatin-state discovery and
1766 characterization. *Nature methods* **9**, 215-216, doi:10.1038/nmeth.1906 (2012).
1767 99 Battle, A., Brown, C. D., Engelhardt, B. E. & Montgomery, S. B. Genetic effects on
1768 gene expression across human tissues. *Nature* **550**, 204-213,
1769 doi:10.1038/nature24277 (2017).
1770 100 Zhernakova, D. V. *et al.* Identification of context-dependent expression quantitative
1771 trait loci in whole blood. *Nature genetics* **49**, 139-145, doi:10.1038/ng.3737 (2017).
1772 101 Westra, H. J. *et al.* Systematic identification of trans eQTLs as putative drivers of
1773 known disease associations. *Nature genetics* **45**, 1238-1243, doi:10.1038/ng.2756
1774 (2013).
1775 102 Joehanes, R. *et al.* Integrated genome-wide analysis of expression quantitative trait
1776 loci aids interpretation of genomic association studies. *Genome biology* **18**, 16,
1777 doi:10.1186/s13059-016-1142-6 (2017).
1778 103 Pers, T. H. *et al.* Biological interpretation of genome-wide association studies using
1779 predicted gene functions. *Nature communications* **6**, 5890,
1780 doi:10.1038/ncomms6890 (2015).
1781